{"id":12718,"date":"2026-02-17T18:46:40","date_gmt":"2026-02-17T18:46:40","guid":{"rendered":"https:\/\/csiag.eu\/?p=12718"},"modified":"2026-02-17T20:56:03","modified_gmt":"2026-02-17T20:56:03","slug":"ochorenie-spojene-s-protilatkami-mogad","status":"publish","type":"post","link":"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/","title":{"rendered":"MOGAD - choroba spojen\u00e1 s protil\u00e1tkami proti MOG"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_87_1 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Obsah<\/p>\n<span class=\"ez-toc-title-toggle\"><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Was_ist_MOGAD\" >\u010co je MOGAD?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Was_geht_bei_MOGAD_schief\" >\u010co sa deje v spolo\u010dnosti MOGAD?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wo_im_Korper_passiert_das\" >Kde v tele sa to deje?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wie_verlauft_die_Erkrankung\" >Ako choroba postupuje?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wie_haufig_ist_MOGAD\" >Ako \u010dast\u00fd je MOGAD?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Was_lost_MOGAD_aus\" >\u010co sp\u00fa\u0161\u0165a MOGAD?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wie_wird_MOGAD_behandelt\" >Ako sa lie\u010di MOGAD?<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wissenschaftliche_Einleitung_und_Definition\" >Vedeck\u00fd \u00favod a defin\u00edcia<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Abgrenzung_von_MOGAD_NMOSD_und_MS\" >Rozl\u00ed\u0161enie medzi MOGAD, NMOSD a MS<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOG-Protein_%E2%80%93_Struktur_und_physiologische_Funktion\" >Prote\u00edn MOG - \u0161trukt\u00fara a fyziologick\u00e1 funkcia<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Strukturdomanen\" >\u0160truktur\u00e1lne dom\u00e9ny<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Physiologische_Funktionen\" >Fyziologick\u00e9 funkcie<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Pathogenese_und_Immunpathologie\" >Patogen\u00e9za a imunopatol\u00f3gia<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Trigger_und_initiale_Aktivierung\" >Sp\u00fa\u0161\u0165a\u010d a po\u010diato\u010dn\u00e1 aktiv\u00e1cia<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#T-Zell-vermittelte_Pathogenese\" >Patogen\u00e9za sprostredkovan\u00e1 T-bunkami<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_1_%E2%80%93_Periphere_Aktivierung\" >F\u00e1za 1 - Perif\u00e9rna aktiv\u00e1cia<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_2_%E2%80%93_BHS-Penetration\" >F\u00e1za 2 - prenikanie BHS<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_3_%E2%80%93_Perivaskulare_Reaktivierung\" >F\u00e1za 3 - Perivaskul\u00e1rna reaktiv\u00e1cia<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#B-Zell-_und_Antikorper-vermittelte_Pathogenese\" >Patogen\u00e9za sprostredkovan\u00e1 B-bunkami a protil\u00e1tkami<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Molekulare_Signalwege_und_Effektormechanismen\" >Molekul\u00e1rne sign\u00e1lne dr\u00e1hy a efektorov\u00e9 mechanizmy<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_1_%E2%80%93_Klassischer_Komplementweg_CDC\" >Sign\u00e1lna dr\u00e1ha 1 - klasick\u00e1 komplementov\u00e1 dr\u00e1ha (CDC)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_2_%E2%80%93_Fc%CE%B3-Rezeptor-Weg_FcR-vermittelt\" >Sign\u00e1lna dr\u00e1ha 2 - dr\u00e1ha receptora Fc\u03b3 (sprostredkovan\u00e1 FcR)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_3_%E2%80%93_IL-6JAK-STAT3-Weg\" >Sign\u00e1lna dr\u00e1ha 3 - dr\u00e1ha IL-6\/JAK-STAT3<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_4_%E2%80%93_MAPK-_und_AKT-Signalwege_B-Zellen\" >Sign\u00e1lna dr\u00e1ha 4 - MAPK a AKT sign\u00e1lne dr\u00e1hy (B bunky)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_5_%E2%80%93_Th17-Zytokin-Netzwerk_im_ZNS\" >Sign\u00e1lna dr\u00e1ha 5 - sie\u0165 cytok\u00ednov Th17 v CNS<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalwege_%E2%80%93_Ubersicht\" >Sign\u00e1lne dr\u00e1hy - preh\u013ead<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Relevante_Rezeptoren_und_Zielmolekule\" >Relevantn\u00e9 receptory a cie\u013eov\u00e9 molekuly<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOG_selbst_als_Zielstruktur_kein_klassischer_Rezeptor\" >samotn\u00fd MOG ako cie\u013eov\u00e1 \u0161trukt\u00fara (nie klasick\u00fd receptor)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Fc%CE%B3-Rezeptoren_Fc%CE%B3R\" >Receptory Fc\u03b3 (Fc\u03b3R)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Neonataler_Fc-Rezeptor_FcRn\" >Novorodeneck\u00fd Fc receptor (FcRn)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-31\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#IL-6-Rezeptor_IL-6R%CE%B1_gp130\" >Receptor IL-6 (IL-6R\u03b1 \/ gp130)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-32\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#T-Zell-Rezeptor_TCR_und_Kostimulationsmolekule\" >T-bunkov\u00fd receptor (TCR) a kostimula\u010dn\u00e9 molekuly<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-33\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Komplementrezeptoren\" >Receptory komplementu<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-34\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Histopathologie_und_ZNS-Lasionsmuster\" >Histopatol\u00f3gia a vzor l\u00e9zie CNS<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-35\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Klinische_Manifestationen_und_Phanotypen\" >Klinick\u00e9 prejavy a fenotypy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-36\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Diagnostik\" >Diagnostika<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-37\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Therapeutische_Strategien\" >Terapeutick\u00e9 strat\u00e9gie<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-38\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Akuttherapie_Schubbehandlung\" >Ak\u00fatna lie\u010dba (lie\u010dba relapsu)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-39\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Prophylaktische_Langzeittherapie\" >Profylaktick\u00e1 dlhodob\u00e1 lie\u010dba<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-40\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Klinische_Studien_%E2%80%93_2024%E2%80%932026\" >Klinick\u00e9 \u0161t\u00fadie - 2024-2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-41\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Neue_und_zukunftige_Therapiekonzepte\" >Nov\u00e9 a bud\u00face koncepcie lie\u010dby<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-42\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#BTK-Inhibitoren_Bruton-Tyrosin-Kinase\" >Inhib\u00edtory BTK (Brutonova tyroz\u00ednkin\u00e1za)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-43\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Toleranzinduktion_MOG-Tolerisierung\" >Navodenie tolerancie (tolerancia MOG)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-44\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Komplementinhibitoren\" >Inhib\u00edtory komplementu<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-45\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Anti-Neonatal-Fc-Rezeptor-Strategien\" >Strat\u00e9gie proti neonat\u00e1lnemu Fc receptoru<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-46\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Autologe_hamatopoetische_Stammzelltransplantation_aHSCT\" >Autol\u00f3gna transplant\u00e1cia krvotvorn\u00fdch kme\u0148ov\u00fdch buniek (aHSCT)<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-47\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Biomarker_und_Verlaufsmonitoring\" >Biomarkery a n\u00e1sledn\u00e9 monitorovanie<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-48\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Prognose_und_Besonderheiten\" >Predpove\u010f a \u0161peci\u00e1lne funkcie<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-49\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Zusammenfassung_und_Ausblick\" >Zhrnutie a v\u00fdh\u013ead<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-50\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Atherischer_Ole_%E2%80%93_Wirkstoffe_nach_Signalwegen_geordnet\" >Esenci\u00e1lne oleje - \u00fa\u010dinn\u00e9 l\u00e1tky zoraden\u00e9 pod\u013ea sign\u00e1lnych dr\u00e1h<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-51\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Weihrauch_Boswellia_serrata_%E2%80%93_AKBA_und_Incensolacetat\" >Kadidlo (Boswellia serrata) - AKBA a incensol acet\u00e1t<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-52\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Therapeutisch_relevante_AKBA-Zieldosen\" >Terapeuticky relevantn\u00e9 cie\u013eov\u00e9 d\u00e1vky AKBA<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-53\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Umrechnung_auf_375_mg_AKBA_jeKapsel\" >Konverzia na 37,5 mg AKBA na kapsulu<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-54\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wichtige_Einnahmehinweise\" >D\u00f4le\u017eit\u00e9 pokyny pre pr\u00edjem<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-55\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Schwarzer_Pfeffer_oral\" >\u010cierne korenie (peror\u00e1lne)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-56\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Schwarzer_Pfeffer_Inhalation\" >\u010cierne korenie (inhal\u00e1cia)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-57\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Copaiba-Ol_oral_%E2%80%93_NUR_doTERRA\" >Olej z kopaiby (or\u00e1lny) - iba doTERRA<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-58\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOGAD-spezifische_Dosierungstabelle_doTERRA_Copaiba_525_BCP\" >Tabu\u013eka d\u00e1vkovania \u0161pecifick\u00e1 pre MOGAD (doTERRA Copaiba 52,5 % BCP)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-59\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOGAD-Phasen-adaptierte_Dosierung\" >F\u00e1zovo prisp\u00f4soben\u00e9 d\u00e1vkovanie MOGAD<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-60\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_1_Akuter_Schub_erste_2%E2%80%934_Wochen\" >F\u00e1za 1: Ak\u00fatne vzplanutie (prv\u00e9 2-4 t\u00fd\u017edne)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-61\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_2_Schubremission_Erhaltung_langfristig\" >F\u00e1za 2: remisia relapsu \/ udr\u017eiavanie (dlhodob\u00e9)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-62\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_3_Monophasischer_Verlauf_Titer_fallend\" >F\u00e1za 3: Monof\u00e1zick\u00fd priebeh (klesaj\u00faci titer)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-63\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Quellen\" >Zdroje<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-64\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Copaiba-Ol_Inhalation\" >Olej z kopaiby (inhal\u00e1cia)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-65\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Zieldosen_und_benotigte_Tropfenzahl\" >Cie\u013eov\u00e9 d\u00e1vky a po\u017eadovan\u00fd po\u010det kvapiek<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-66\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Synergistische_MOGAD-Strategie_Multi-Target\" >Synergick\u00e1 strat\u00e9gia MOGAD (viac\u00fa\u010delov\u00e1)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-67\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wichtige_MOGAD-spezifische_Hinweise\" >D\u00f4le\u017eit\u00e9 inform\u00e1cie \u0161pecifick\u00e9 pre MOGAD<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-68\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#%CE%B1-Asaron_Kalmus-Ol_Acorus_calamus_%E2%80%93_direkt_oligodendrozytenprotektiv\" >\u03b1-Asaron (kalam\u00e1rov\u00fd olej, Acorus calamus) - priamo oligodendrocytovo protekt\u00edvny<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-69\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Geraniumol_Pelargonium_graveolens_%E2%80%93_Neuroinflammation_und_NO\" >Ger\u00e1niov\u00fd olej (Pelargonium graveolens) - neuroz\u00e1pal a NO<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-70\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Teebaum-Ol_Melaleuca_alternifolia_%E2%80%93_Mikroglia-Modulation\" >\u010cajovn\u00edkov\u00fd olej (Melaleuca alternifolia) - modul\u00e1cia mikroglie<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-71\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wirkstoffubersicht_nach_MOGAD-Signalwegen\" >Preh\u013ead \u00fa\u010dinn\u00fdch l\u00e1tok pod\u013ea sign\u00e1lnych dr\u00e1h MOGAD<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-72\" href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Quellen_und_weiterfuhrende_Literatur\" >Zdroje a \u010fal\u0161ia literat\u00fara<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">\u010cas \u010d\u00edtania<\/span> <span class=\"rt-time\"> 17<\/span> <span class=\"rt-label rt-postfix\">z\u00e1pisnice<\/span><\/span>\n<p class=\"wp-block-paragraph\"><em>Ochorenie spojen\u00e9 s myel\u00ednov\u00fdm oligodendrocytov\u00fdm glykoprote\u00ednom<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_ist_MOGAD\"><\/span>\u010co je MOGAD?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ka\u017ed\u00fd pozn\u00e1 elektrick\u00e9 k\u00e1ble: S\u00fa vybaven\u00e9 izol\u00e1ciou, ktor\u00e1 odde\u013euje jednotliv\u00e9 vodi\u010de v k\u00e1blovom zv\u00e4zku od seba, aby sa sign\u00e1ly v nich navz\u00e1jom neru\u0161ili a dostali sa z bodu A do bodu B bez ru\u0161enia.<br>Miecha obsahuje cel\u00fd rad tak\u00fdchto k\u00e1blov\u00fdch zv\u00e4zkov. Ved\u00fa nervov\u00e9 sign\u00e1ly z mozgu do r\u00f4znych org\u00e1nov, svalov, tkan\u00edv at\u010f. v tele. Zatia\u013e \u010do izol\u00e1cia k\u00e1bla je vyroben\u00e1 z plastu, textilu alebo \u0161peci\u00e1lnych materi\u00e1lov, izola\u010dn\u00e1 vrstva miechy je vyroben\u00e1 zo \u0161peci\u00e1lneho materi\u00e1lu. <strong>Myel\u00ednov\u00e1 vrstva<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_geht_bei_MOGAD_schief\"><\/span>\u010co sa deje v spolo\u010dnosti MOGAD?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">V pr\u00edpade MOGAD sa imunitn\u00fd syst\u00e9m tela dopust\u00ed z\u00e1va\u017enej chyby: omylom produkuje <strong>Protil\u00e1tky proti \u0161pecifick\u00e9mu prote\u00ednu na vonkaj\u0161ej strane tejto izola\u010dnej vrstvy<\/strong>, tzv. <strong>MOG<\/strong>-prote\u00edn. Protil\u00e1tky s\u00fa vlastne ochrancovia tela, ktor\u00ed rozpozn\u00e1vaj\u00fa, ozna\u010duj\u00fa a ni\u010dia patog\u00e9ny, ako s\u00fa v\u00edrusy a bakt\u00e9rie. Pri MOGAD s\u00fa v\u0161ak omylom namieren\u00e9 proti zdrav\u00e9mu tkanivu tela, proti izol\u00e1cii vlastn\u00fdch nervov\u00fdch vl\u00e1kien.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">V porovnan\u00ed s k\u00e1blom je to ako po\u0161kriabanie, obrusovanie alebo kor\u00f3zia izol\u00e1cie, \u010do sp\u00f4sob\u00ed jej perfor\u00e1ciu a elektrick\u00e9 sign\u00e1ly sa u\u017e nedostan\u00fa na miesto ur\u010denia \u010disto alebo dokonca v\u00f4bec.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wo_im_Korper_passiert_das\"><\/span>Kde v tele sa to deje?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD sa t\u00fdka v\u00fdlu\u010dne <strong>Centr\u00e1lny nervov\u00fd syst\u00e9m<\/strong>, t. j. mozog, miechu a zrakov\u00e9 nervy. V z\u00e1vislosti od toho, ktor\u00e1 oblas\u0165 je postihnut\u00e1, vznikaj\u00fa r\u00f4zne pr\u00edznaky:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Zrakov\u00fd nerv<\/strong> - N\u00e1hla strata zraku, rozmazan\u00e9 videnie, boles\u0165 o\u010d\u00ed (\u010dasto len na jednom oku, niekedy na oboch o\u010diach s\u00fa\u010dasne - pri MOGAD je to \u010dastej\u0161ie ako pri in\u00fdch podobn\u00fdch ochoreniach)<\/li>\n\n\n\n<li><strong>Miecha<\/strong> - Pr\u00edznaky ochrnutia, necitlivosti, probl\u00e9my s mo\u010den\u00edm<\/li>\n\n\n\n<li><strong>Mozog :<\/strong> Zm\u00e4tenos\u0165, epileptick\u00e9 z\u00e1chvaty, poruchy koordin\u00e1cie<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wie_verlauft_die_Erkrankung\"><\/span>Ako choroba postupuje?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD zvy\u010dajne prebieha v <strong>Stla\u010d\u00ed<\/strong>. Existuj\u00fa f\u00e1zy, v ktor\u00fdch je z\u00e1pal akt\u00edvny a objavuj\u00fa sa pr\u00edznaky, s prest\u00e1vkami a pokojnej\u0161\u00edmi f\u00e1zami medzi nimi.<br>Mnoh\u00ed pacienti sa po epiz\u00f3de prekvapivo dobre zotavuj\u00fa, lep\u0161ie ako napr\u00edklad pri SM. Je to preto, \u017ee samotn\u00e9 nervov\u00e9 vl\u00e1kna s\u00fa \u010dasto menej pravdepodobne trvalo po\u0161koden\u00e9 ako izola\u010dn\u00e1 vrstva, ktor\u00e1 sa m\u00f4\u017ee \u010diasto\u010dne regenerova\u0165.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pribli\u017ene polovica postihnut\u00fdch za\u017eije po\u010das \u017eivota len jedno vzplanutie. Druh\u00e1 polovica m\u00e1 opakovan\u00e9 pr\u00edhody, ktor\u00e9 m\u00f4\u017eu vies\u0165 k trval\u00e9mu po\u0161kodeniu, ak sa nelie\u010dia.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wie_haufig_ist_MOGAD\"><\/span>Ako \u010dast\u00fd je MOGAD?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD je zriedkav\u00fd, iba odhadovan\u00fd <strong>1-2 zo 100 000 \u013eud\u00ed<\/strong> ochorie. Na rozdiel od mnoh\u00fdch in\u00fdch autoimunitn\u00fdch ochoren\u00ed nervov\u00e9ho syst\u00e9mu postihuje \u017eeny a mu\u017eov v pribli\u017ene rovnakom po\u010dte. Ochorenie sa m\u00f4\u017ee vyskytn\u00fa\u0165 aj u det\u00ed, pri\u010dom sa \u010dasto prejavuje ako rozsiahly z\u00e1pal mozgu so zm\u00e4tenos\u0165ou a hor\u00fa\u010dkou.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_lost_MOGAD_aus\"><\/span>\u010co sp\u00fa\u0161\u0165a MOGAD?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Po prvej epiz\u00f3de \u010dasto nasleduje <strong>Infekcia<\/strong> dopredu. Telo bojuje proti patog\u00e9nu a mylne si zamie\u0148a vlastn\u00e9 \u0161trukt\u00fary s nepriate\u013eom. Imunitn\u00fd syst\u00e9m sa nau\u010d\u00ed \u00fato\u010di\u0165 takpovediac na nespr\u00e1vny cie\u013e a nikdy sa nezastav\u00ed. Presn\u00e1 pr\u00ed\u010dina e\u0161te nie je \u00faplne objasnen\u00e1. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wie_wird_MOGAD_behandelt\"><\/span>Ako sa lie\u010di MOGAD?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">V s\u00fa\u010dasnosti neexistuje \u017eiadny \u0161peci\u00e1lne povolen\u00fd liek na MOGAD. Jeden <strong>ak\u00fatny z\u00e1chvat<\/strong> sa lie\u010di vysok\u00fdmi d\u00e1vkami <strong>Kortiz\u00f3nov\u00e9 inf\u00fazie<\/strong>, ktor\u00e9 r\u00fdchlo tlmia z\u00e1pal. Ak to nesta\u010d\u00ed <strong>Um\u00fdvanie krvi<\/strong> (<em>Plazmafer\u00e9za<\/em>) sa \u0161kodliv\u00e1 protil\u00e1tka m\u00f4\u017ee odstr\u00e1ni\u0165 priamo z krvi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Na <strong>Prevencia \u010fal\u0161\u00edch recid\u00edv<\/strong> Na upokojenie imunitn\u00e9ho syst\u00e9mu sa pou\u017e\u00edvaj\u00fa r\u00f4zne lieky, napr\u00edklad l\u00e1tky, ktor\u00e9 zni\u017euj\u00fa po\u010det buniek produkuj\u00facich protil\u00e1tky. V s\u00fa\u010dasnosti sa v klinick\u00fdch sk\u00fa\u0161kach testuje nieko\u013eko nov\u00fdch, cielenej\u0161\u00edch liekov, ktor\u00e9 by mohli by\u0165 schv\u00e1len\u00e9 v najbli\u017e\u0161\u00edch rokoch.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wissenschaftliche_Einleitung_und_Definition\"><\/span>Vedeck\u00fd \u00favod a defin\u00edcia<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">Str\u00e1nka <strong>Ochorenie spojen\u00e9 s protil\u00e1tkami MOG (MOGAD)<\/strong> Angli\u010dtina: <em>Ochorenie spojen\u00e9 s myel\u00ednov\u00fdm oligodendrocytov\u00fdm glykoprote\u00ednom<\/em> je zriedkav\u00e9 z\u00e1palov\u00e9 autoimunitn\u00e9 ochorenie centr\u00e1lneho nervov\u00e9ho syst\u00e9mu (CNS), ktor\u00e9 je od roku 2018 uznan\u00e9 ako samostatn\u00e1 jednotka s vlastn\u00fdmi diagnostick\u00fdmi krit\u00e9riami. Predt\u00fdm sa pova\u017eovalo za variant skler\u00f3zy multiplex (SM) alebo za poruchu spektra neuromyelitis optica (NMOSD).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Z\u00e1kladn\u00fdm prvkom ochorenia je patologick\u00e1 tvorba autoprotil\u00e1tok (IgG) proti <strong>Myel\u00ednov\u00fd oligodendrocytov\u00fd glykoprote\u00edn (MOG)<\/strong>, transmembr\u00e1nov\u00fd prote\u00edn na vonkaj\u0161ej vrstve myel\u00ednovej po\u0161vy oligodendrocytov v CNS. Tieto protil\u00e1tky po\u0161kodzuj\u00fa myel\u00ednov\u00e9 po\u0161vy a ved\u00fa k charakteristickej perivenul\u00e1rnej demyeliniz\u00e1cii.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Klinicky sa MOGAD prejavuje najm\u00e4 ako optick\u00e1 neurit\u00edda, transverz\u00e1lna myelit\u00edda a ak\u00fatna diseminovan\u00e1 encefalomyelit\u00edda (ADEM). Ochorenie je zvy\u010dajne recidivuj\u00face a postihuje zrakov\u00fd nerv, miechu a zriedkavej\u0161ie mozog. Priemern\u00fd vek za\u010diatku ochorenia je 30 a\u017e 35 rokov; na rozdiel od NMOSD s\u00fa \u017eeny a mu\u017ei postihnut\u00ed takmer rovnako \u010dasto.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Abgrenzung_von_MOGAD_NMOSD_und_MS\"><\/span>Rozl\u00ed\u0161enie medzi MOGAD, NMOSD a MS<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Funkcia<\/strong><\/td><td><strong>MOGAD<\/strong><\/td><td><strong>AQP4+ NMOSD<\/strong><\/td><td><strong>Skler\u00f3za multiplex<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Cie\u013eov\u00fd antig\u00e9n<\/td><td>MOG (oligodendrocyty)<\/td><td>Akvapor\u00edn-4 (astrocyty)<\/td><td>\u017diadna \u0161pecifick\u00e1 autoprotil\u00e1tka<\/td><\/tr><tr><td>Izotyp protil\u00e1tky<\/td><td>IgG1 (pre)<\/td><td>IgG1 (pre)<\/td><td>Oligoklon\u00e1lny IgG (CSF)<\/td><\/tr><tr><td>Prim\u00e1rne po\u0161kodenie buniek<\/td><td>Oligodendrocyty\/myel\u00edn<\/td><td>Astrocyty (prim\u00e1rne)<\/td><td>Oligodendrocyty<\/td><\/tr><tr><td>Histol\u00f3gia<\/td><td>Perivenul\u00e1rna demyeliniz\u00e1cia, CD4+<\/td><td>L\u00e9zie astrocytov, granulocyty<\/td><td>Periaxi\u00e1lne plaky<\/td><\/tr><tr><td>Pohlavie (F:M)<\/td><td>~1:1<\/td><td>~9:1<\/td><td>~3:1<\/td><\/tr><tr><td>Aktiv\u00e1cia komplementu<\/td><td>Mierne (menej MAC)<\/td><td>Strong (form\u00e1cia MAC)<\/td><td>N\u00edzka<\/td><\/tr><tr><td>OKB v mozgovomiechovom moku<\/td><td>Zriedkav\u00e9 (&lt;10%)<\/td><td>Pr\u00edle\u017eitostne<\/td><td>\u010cast\u00e9 (&gt;90%)<\/td><\/tr><tr><td>Kurz<\/td><td>Recidivuj\u00face; \u010dasto dobre zotaven\u00e9<\/td><td>\u0164ahov\u00fd tvar; akumuluje zdravotn\u00e9 postihnutie<\/td><td>\u010casto progedientn\u00e9<\/td><\/tr><tr><td>Autorizovan\u00e9 terapie<\/td><td>\u017diadne (od roku 2026)<\/td><td>Ekulizumab, ublituximab, satralizumab<\/td><td>Mnoh\u00e9 DMT<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOG-Protein_%E2%80%93_Struktur_und_physiologische_Funktion\"><\/span>Prote\u00edn MOG - \u0161trukt\u00fara a fyziologick\u00e1 funkcia<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">MOG (myel\u00ednov\u00fd oligodendrocytov\u00fd glykoprote\u00edn) je <strong>Transmembr\u00e1nov\u00fd prote\u00edn typu I<\/strong> s celkovou d\u013a\u017ekou 218 aminokysel\u00edn, ktor\u00fd je exprimovan\u00fd v\u00fdlu\u010dne v CNS. Je \u010dlenom imunoglobul\u00ednovej superrodiny a s podielom pribli\u017ene 0,01 - 0,05 % z celkov\u00e9ho myel\u00ednov\u00e9ho prote\u00ednu predstavuje kvantitat\u00edvne mal\u00fa, ale imunologicky ve\u013emi v\u00fdznamn\u00fa zlo\u017eku myel\u00ednovej po\u0161vy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Strukturdomanen\"><\/span>\u0160truktur\u00e1lne dom\u00e9ny<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Extracelul\u00e1rna dom\u00e9na podobn\u00e1 Ig-V (AS 1-120): Obsahuje kritick\u00fa oblas\u0165 CC\u2018 slu\u010dky (Pro42, His103, Ser104) ako najd\u00f4le\u017eitej\u0161ie epitopov\u00e9 v\u00e4zobn\u00e9 miesto pre MOG-IgG<\/li>\n\n\n\n<li>Jednopriechodov\u00e1 transmembr\u00e1nov\u00e1 \u0161pir\u00e1la: ukotvuje prote\u00edn v myel\u00ednovej membr\u00e1ne<\/li>\n\n\n\n<li>Kr\u00e1tka cytoplazmatick\u00e1 C-koncov\u00e1 dom\u00e9na: pravdepodobne interaguje s cytoskeletom<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Physiologische_Funktionen\"><\/span>Fyziologick\u00e9 funkcie<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Adh\u00e9zna molekula: Sprostredk\u00fava \u0161truktur\u00e1lnu integritu myel\u00ednovej po\u0161vy, pravdepodobne t\u00fdm, \u017ee zhut\u0148uje myel\u00ednov\u00e9 lamely<\/li>\n\n\n\n<li>Interakcia s C1q komplementov\u00e9ho syst\u00e9mu (fyziologick\u00e1)<\/li>\n\n\n\n<li>Interakcia s nervov\u00fdm rastov\u00fdm faktorom (NGF)<\/li>\n\n\n\n<li>Receptor pre v\u00edrus rubeoly (klinicky relevantn\u00fd pre postinfek\u010dn\u00fa ADEM)<\/li>\n\n\n\n<li>Stabiliz\u00e1cia mikrotubulov v oligodendrocytoch<\/li>\n\n\n\n<li>Expresia: neskoro v diferenci\u00e1cii oligodendrocytov; len po po\u010diato\u010dnej myeliniz\u00e1cii<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Autoprotil\u00e1tky MOG-IgG rozpozn\u00e1vaj\u00fa predov\u0161etk\u00fdm <strong>Konforma\u010dn\u00e9 epitopy<\/strong> extracelul\u00e1rnej dom\u00e9ny. Ke\u010f\u017ee MOG je vystaven\u00fd na vonkaj\u0161om povrchu myel\u00ednovej po\u0161vy, je priamo pr\u00edstupn\u00fd cirkuluj\u00facim protil\u00e1tkam a imunitn\u00fdm komplexom, \u010do je rozhoduj\u00faci rozdiel oproti intracelul\u00e1rnym antig\u00e9nom.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pathogenese_und_Immunpathologie\"><\/span>Patogen\u00e9za a imunopatol\u00f3gia<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">Patogen\u00e9za MOGAD je viacstup\u0148ov\u00fd proces, ktor\u00fd zah\u0155\u0148a aktiv\u00e1ciu perif\u00e9rneho imunitn\u00e9ho syst\u00e9mu, migr\u00e1ciu cez hematoencefalick\u00fa bari\u00e9ru (BBB) a lok\u00e1lne efektorov\u00e9 mechanizmy v CNS. Samotn\u00e9 T-lymfocyty ani B-lymfocyty nie s\u00fa dostato\u010dne patog\u00e9nne, ochorenie sp\u00f4sobuje synergick\u00e1 interakcia oboch ramien adapt\u00edvneho imunitn\u00e9ho syst\u00e9mu.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Trigger_und_initiale_Aktivierung\"><\/span>Sp\u00fa\u0161\u0165a\u010d a po\u010diato\u010dn\u00e1 aktiv\u00e1cia<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Hlavn\u00fdmi po\u010diato\u010dn\u00fdmi sp\u00fa\u0161\u0165a\u010dmi s\u00fa <strong>Infekcie<\/strong> diskutovali: Infek\u010dn\u00fd prodr\u00f3m bol zdokumentovan\u00fd u 37-70 % pacientov s MOGAD (\u010dastej\u0161ie ako u NMOSD s 15-35 %). Mechanizmy zah\u0155\u0148aj\u00fa:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Molekul\u00e1rna mimikry - epitopy patog\u00e9nov s\u00fa \u0161truktur\u00e1lne podobn\u00e9 oblasti CC\u2018 slu\u010dky MOG, napr. sekvencie SARS-CoV-2 alebo v\u00edrusy rubeoly<\/li>\n\n\n\n<li>Aktiv\u00e1cia okolia - ne\u0161pecifick\u00e1 z\u00e1palov\u00e1 reakcia aktivuje neakt\u00edvne autoreakt\u00edvne lymfocyty<\/li>\n\n\n\n<li>Polyklon\u00e1lna aktiv\u00e1cia B-buniek mikrobi\u00e1lnymi superantig\u00e9nmi<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Genetick\u00e1 predispoz\u00edcia zohr\u00e1va ur\u010dit\u00fa \u00falohu, ale \u0161pecifick\u00e9 rizikov\u00e9 haplotypy neboli jednozna\u010dne identifikovan\u00e9. Na rozdiel od SM neboli op\u00edsan\u00e9 \u017eiadne konzistentn\u00e9 HLA asoci\u00e1cie.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"T-Zell-vermittelte_Pathogenese\"><\/span>Patogen\u00e9za sprostredkovan\u00e1 T-bunkami<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">MOG \u0161pecifick\u00e9 CD4+ T bunky s\u00fa nevyhnutn\u00e9 pre patogen\u00e9zu MOGAD. V zvierac\u00edch modeloch (EAE) samotn\u00e9 protil\u00e1tky nie s\u00fa patog\u00e9nne; vy\u017eaduj\u00fa encefalitog\u00e9nne T-bunky ako ko-\u00fa\u010dinkuj\u00face. Cesta CD4+ pozost\u00e1va z nieko\u013ek\u00fdch f\u00e1z:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_1_%E2%80%93_Periphere_Aktivierung\"><\/span>F\u00e1za 1 - Perif\u00e9rna aktiv\u00e1cia<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">MOG peptidy s\u00fa produkovan\u00e9 antig\u00e9n-prezentuj\u00facimi bunkami (APC) prostredn\u00edctvom <strong>Molekuly MHC-II<\/strong> naivn\u00fdm CD4+ T-bunk\u00e1m. Za zmienku stoj\u00ed: <em>Peptidy MOG sa m\u00f4\u017eu viaza\u0165 priamo na perif\u00e9rne molekuly MHC II<\/em>, bez \u010fal\u0161ieho spracovania. To by mohlo vysvetli\u0165 zapojenie perif\u00e9rneho nervov\u00e9ho syst\u00e9mu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Podskupiny efektorov\u00fdch buniek, ktor\u00e9 m\u00f4\u017eu nez\u00e1visle od seba indukova\u0165 EAE, s\u00fa <strong>Th1, Th17 a Th9<\/strong>. Bunky Th17 s\u00fa obzvl\u00e1\u0161\u0165 d\u00f4le\u017eit\u00e9 pre MOGAD, preto\u017ee cytok\u00edny Th17 (IL-17, IL-21) s\u00fa v\u00fdrazne zv\u00fd\u0161en\u00e9 po\u010das epiz\u00f3d strihania.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_2_%E2%80%93_BHS-Penetration\"><\/span>F\u00e1za 2 - prenikanie BHS<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Aktivovan\u00e9 CD4+ T bunky exprimuj\u00fa \u0161pecifick\u00e9 adh\u00e9zne molekuly (integr\u00edny, selekt\u00edny) a chemok\u00ednov\u00e9 receptory (najm\u00e4 <strong>CCR6<\/strong>), ktor\u00e9 im umo\u017e\u0148uj\u00fa vstup do CNS. CCR6+ Th17 bunky sa via\u017eu na CCL20, ktor\u00fd je kon\u0161titut\u00edvne exprimovan\u00fd v choroid\u00e1lnom plexe, a jeho prostredn\u00edctvom vstupuj\u00fa do subarachnoid\u00e1lneho priestoru.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Matrixov\u00e9 metaloprotein\u00e1zy (MMP-2, MMP-9)<br>Degrad\u00e1cia baz\u00e1lnej membr\u00e1ny BBB<\/li>\n\n\n\n<li>Neutrofiln\u00e9 NET (extracelul\u00e1rne lapa\u010de neutrofilov)<br>poskytuj\u00fa kostimula\u010dn\u00e9 sign\u00e1ly pre T-bunky v inicia\u010dnej f\u00e1ze<\/li>\n\n\n\n<li>Trombocyty<br>Podpora prolifer\u00e1cie CD4+ T buniek a ich diferenci\u00e1cie na Th1\/Th17 prostredn\u00edctvom cytok\u00ednov a adh\u00e9znych molek\u00fal<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_3_%E2%80%93_Perivaskulare_Reaktivierung\"><\/span>F\u00e1za 3 - Perivaskul\u00e1rna reaktiv\u00e1cia<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">V perivaskul\u00e1rnom a subarachnoid\u00e1lnom priestore s\u00fa MOG-\u0161pecifick\u00e9 T-lymfocyty reaktivovan\u00e9 lok\u00e1lnymi APC s MOG (mikroglia, dendritick\u00e9 bunky). T\u00e1to reaktiv\u00e1cia sp\u00fa\u0161\u0165a vlastn\u00fa z\u00e1palov\u00fa kask\u00e1du: Vylu\u010dovanie proz\u00e1palov\u00fdch cytok\u00ednov, n\u00e1bor \u010fal\u0161\u00edch leukocytov a po\u0161kodenie oligodendrocytov.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"B-Zell-_und_Antikorper-vermittelte_Pathogenese\"><\/span>Patogen\u00e9za sprostredkovan\u00e1 B-bunkami a protil\u00e1tkami<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">MOG-\u0161pecifick\u00e9 B-bunky a plazmatick\u00e9 bunky s\u00fa hlavn\u00fdmi producentmi patog\u00e9nnych autoprotil\u00e1tok IgG1. \u00daloha B buniek v\u0161ak presahuje produkciu protil\u00e1tok:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Prezent\u00e1cia antig\u00e9nu - B bunky m\u00f4\u017eu viaza\u0165 konforma\u010dn\u00e9 epitopy MOG (pro42, his103, ser104 slu\u010dky CC\u2018) prostredn\u00edctvom svojho BCR a p\u00f4sobi\u0165 ako APC pre T bunky<\/li>\n\n\n\n<li>Podpora diferenci\u00e1cie Th17 - B bunky vylu\u010duj\u00fa IL-6, ktor\u00fd spolu s TGF-\u03b2 podporuje diferenci\u00e1ciu Th17<\/li>\n\n\n\n<li>Aktiv\u00e1cia signaliz\u00e1cie MAPK a AKT - v\u00e4zba BCR na MOG aktivuje tieto sign\u00e1lne dr\u00e1hy intracelul\u00e1rne<\/li>\n\n\n\n<li>Zv\u00fd\u0161enie intracelul\u00e1rneho v\u00e1pnika - vedie k aktiv\u00e1cii signaliza\u010dn\u00fdch kask\u00e1d s\u00favisiacich so stresom<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">V\u00e4\u010d\u0161ina protil\u00e1tok MOG-IgG sa vytv\u00e1ra na perif\u00e9rii (oligoklon\u00e1lne p\u00e1sy v CSF len v ~10 % pr\u00edpadoch, pre porovnanie: SM ~90 %). Protil\u00e1tky s\u00fa <strong>dvojzlo\u017ekov\u00e1 v\u00e4zba<\/strong> na MOG sa obe ramen\u00e1 Fab via\u017eu s\u00fa\u010dasne na dve susedn\u00e9 molekuly MOG. To vedie k menej \u00fa\u010dinn\u00e9mu n\u00e1boru C1q v porovnan\u00ed s monovalentnou v\u00e4zbou AQP4-IgG v NMOSD.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Molekulare_Signalwege_und_Effektormechanismen\"><\/span>Molekul\u00e1rne sign\u00e1lne dr\u00e1hy a efektorov\u00e9 mechanizmy<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_1_%E2%80%93_Klassischer_Komplementweg_CDC\"><\/span>Sign\u00e1lna dr\u00e1ha 1 - klasick\u00e1 komplementov\u00e1 dr\u00e1ha (CDC)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ke\u010f sa MOG-IgG1 (a MOG-IgG3) navia\u017ee na oligodendrocyt\u00e1rny MOG. <strong>klasick\u00e1 doplnkov\u00e1 trasa<\/strong> s\u00fa aktivovan\u00e9. Aktiv\u00e1cia komplementu pri MOGAD je v\u0161ak slab\u0161ia ako pri AQP4+ NMOSD:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>V\u00e4zba C1q na Fc \u010das\u0165 viazan\u00fdch protil\u00e1tok IgG1 \u2192 aktiv\u00e1cia C1r a C1s<\/li>\n\n\n\n<li>\u0160tiepenie C4 \u2192 C4a + C4b; C4b + C2 \u2192 C3 konvert\u00e1za (C4b2a)<\/li>\n\n\n\n<li>\u0160tiepenie C3 \u2192 C3a (anafylatox\u00edn) + C3b (opson\u00edn)<\/li>\n\n\n\n<li>C3b \u2192 C5 konvert\u00e1za \u2192 \u0161tiepenie C5 \u2192 C5a (siln\u00fd anafylatox\u00edn) + C5b<\/li>\n\n\n\n<li>C5b + C6, C7, C8, C9 \u2192 membr\u00e1nov\u00fd \u00fato\u010dn\u00fd komplex (MAC, C5b-9): Priama l\u00fdza oligodendrocytov<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">D\u00f4le\u017eit\u00e9: V CSF pacientov s MOGAD s\u00fa C3a a C5a v\u00fdznamne zv\u00fd\u0161en\u00e9 (porovnate\u013en\u00e9 s AQP4+ NMOSD), ale MAC komplex (C5b-9) nie je v\u00fdznamne zv\u00fd\u0161en\u00fd. <strong>v\u00fdrazne ni\u017e\u0161ia<\/strong> ako v NMOSD. Je to sp\u00f4soben\u00e9 bivalentnou v\u00e4zbou IgG, ktor\u00e1 je menej \u00fa\u010dinn\u00e1 pre zhlukovanie C1q, a relat\u00edvne n\u00edzkou hustotou regul\u00e1torov komplementu na oligodendrocytoch (menej CR1, MCP, HRF ako na in\u00fdch typoch buniek).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_2_%E2%80%93_Fc%CE%B3-Rezeptor-Weg_FcR-vermittelt\"><\/span>Sign\u00e1lna dr\u00e1ha 2 - dr\u00e1ha receptora Fc\u03b3 (sprostredkovan\u00e1 FcR)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">V\u00fdskum LMU (Mader, Kawakami, Meinl, 2024 PNAS) uk\u00e1zal, \u017ee mechanizmy sprostredkovan\u00e9 receptorom Fc\u03b3 (Fc\u03b3R) <strong>na pribli\u017ene 50 % po\u0161kodenia myel\u00ednu<\/strong> a s\u00fa preto rovnocenn\u00e9 s aktiv\u00e1ciou komplementu:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fc\u03b3RIII<\/strong> (<strong>CD16<\/strong>) na NK bunky a makrof\u00e1gy<br>Via\u017ee Fc \u010das\u0165 IgG1 viazan\u00e9ho na MOG \u2192 ADCC (bunkov\u00e1 cytotoxicita z\u00e1visl\u00e1 od protil\u00e1tok)<\/li>\n\n\n\n<li><strong>Fc\u03b3RI\/II\/III<\/strong> na makrof\u00e1goch a monocytoch<br>Fagocyt\u00f3za fragmentov oligodendrocytov s opsonizovan\u00fdm MOG (ADCP)<\/li>\n\n\n\n<li>Rozhoduj\u00face: druh\u00fd patomechanizmus FcR<br>Zv\u00fd\u0161enie aktiv\u00e1cie T-buniek prebieha v\u00fdlu\u010dne prostredn\u00edctvom Fc receptorov, NIE prostredn\u00edctvom komplementovej dr\u00e1hy<\/li>\n\n\n\n<li><strong>Fc\u03b3R<\/strong> na dendritick\u00fdch bunk\u00e1ch<br>U\u013eah\u010denie spracovania a prezent\u00e1cie oligodendrocytov\u00fdch antig\u00e9nov s obsahom MOG-IgG pre T-lymfocyty \u0161pecifick\u00e9 pre MOG<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Klinick\u00fd v\u00fdznam: Ke\u010f\u017ee existuj\u00fa dve nez\u00e1visl\u00e9 patog\u00e9nne cesty, terapeutick\u00e9 pr\u00edstupy musia by\u0165 <strong>Oba mechanizmy<\/strong> aby sa dosiahla maxim\u00e1lna \u00fa\u010dinnos\u0165.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_3_%E2%80%93_IL-6JAK-STAT3-Weg\"><\/span>Sign\u00e1lna dr\u00e1ha 3 - dr\u00e1ha IL-6\/JAK-STAT3<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">IL-6 je \u00fastredn\u00fdm medi\u00e1torom imunopatogen\u00e9zy MOGAD a p\u00f4sob\u00ed na viacer\u00fdch \u00farovniach:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">IL-6 sa via\u017ee na svoj receptor (komplex IL-6R\u03b1\/gp130), \u010do vedie k <strong>Fosforyl\u00e1cia JAK1\/2<\/strong> vedie. T\u00fdm sa aktivuje predov\u0161etk\u00fdm <strong>STAT3<\/strong>, ktor\u00fd sl\u00fa\u017ei ako transkrip\u010dn\u00fd faktor pre:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Diferenci\u00e1cia Th17<\/strong><br>IL-6 + TGF-\u03b2 \u2192 expresia ROR\u03b3t \u2192 produkcia IL-17A\/F; IL-6 + IL-23 \u2192 udr\u017eanie fenotypu Th17<\/li>\n\n\n\n<li><strong>Folikul\u00e1rne pomocn\u00e9 T-bunky<\/strong> (<strong>Tfh<\/strong>)<br>IL-6 \u2192 STAT3 \u2192 expresia Bcl6 \u2192 dozrievanie B buniek germin\u00e1lneho centra a zmena triedy IgG<\/li>\n\n\n\n<li><strong>dozrievanie B-buniek na plazmatick\u00e9 bunky<\/strong><br>IL-6 podporuje diferenci\u00e1ciu prostredn\u00edctvom osi STAT3\/Blimp-1<\/li>\n\n\n\n<li><strong>Potla\u010denie funkcie Treg<\/strong><br>IL-6 inhibuje expresiu FoxP3, \u010do pos\u00fava rovnov\u00e1hu Treg\/Th17 smerom k z\u00e1palu<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Terapeutick\u00fd v\u00fdznam: Blok\u00e1da IL-6 (napr. tocilizumab, satralizumab) preru\u0161uje tento cyklus. <strong><em>Satralizumab<\/em><\/strong> (anti-IL-6R) sa v s\u00fa\u010dasnosti sk\u00fama v r\u00e1mci \u0161t\u00fadie f\u00e1zy 3 METEOROID pre MOGAD.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_4_%E2%80%93_MAPK-_und_AKT-Signalwege_B-Zellen\"><\/span>Sign\u00e1lna dr\u00e1ha 4 - MAPK a AKT sign\u00e1lne dr\u00e1hy (B bunky)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">V\u00e4zba BCR na konforma\u010dn\u00e9 epitopy MOG aktivovan\u00e9 v B-bunk\u00e1ch:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cesta MAPK<\/strong> (<strong>MEK\/ERK<\/strong>)<br>Podpora prolifer\u00e1cie a diferenci\u00e1cie B-buniek<\/li>\n\n\n\n<li><strong>Cesta PI3K\/AKT<\/strong><br>Pre\u017e\u00edvanie buniek a diferenci\u00e1cia B-buniek na plazmatick\u00e9 bunky<\/li>\n\n\n\n<li><strong>Pr\u00edlev v\u00e1pnika<\/strong><br>Aktiv\u00e1cia osi kalcineur\u00edn\/NFAT \u2192 Produkcia cytok\u00ednov<\/li>\n\n\n\n<li><strong>Aktiv\u00e1cia NK buniek<\/strong><br>V\u00e4zba BCR-MOG indukuje cytotoxicitu sprostredkovan\u00fa NK bunkami<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_5_%E2%80%93_Th17-Zytokin-Netzwerk_im_ZNS\"><\/span>Sign\u00e1lna dr\u00e1ha 5 - sie\u0165 cytok\u00ednov Th17 v CNS<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">V CNS udr\u017eiavaj\u00fa bunky Th17 z\u00e1palov\u00e9 prostredie prostredn\u00edctvom viacer\u00fdch medi\u00e1torov:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IL-17A a IL-17F<\/strong><br>aktivuj\u00fa astrocyty a mikroglie; vyvol\u00e1vaj\u00fa uvo\u013e\u0148ovanie chemok\u00ednov (CXCL-1\/5\/8), ktor\u00e9 verbuj\u00fa neutrofily<\/li>\n\n\n\n<li><strong>IL-21<\/strong> (auto- a parakrinn\u00e9)<br>Zvy\u0161uje diferenci\u00e1ciu Th17; podporuje diferenci\u00e1ciu B-buniek a zmenu triedy IgG (najm\u00e4 IgG1)<\/li>\n\n\n\n<li><strong>IL-22<\/strong><br>Dysregul\u00e1cia integrity BBB<\/li>\n\n\n\n<li><strong>GM-CSF<\/strong> (<strong>prostredn\u00edctvom IL-23<\/strong>)<br>Aktivuje mikroglie a makrof\u00e1gy, zvy\u0161uje lok\u00e1lnu demyeliniz\u00e1ciu<\/li>\n\n\n\n<li><strong>CXCL13<\/strong><br>Chemotaxia B-buniek v perivaskul\u00e1rnych priestoroch \u2192 lok\u00e1lna tvorba protil\u00e1tok<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalwege_%E2%80%93_Ubersicht\"><\/span>Sign\u00e1lne dr\u00e1hy - preh\u013ead<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Cesta sign\u00e1lu<\/strong><\/td><td><strong>K\u013e\u00fa\u010dov\u00e9 molekuly<\/strong><\/td><td><strong>\u00da\u010dinok<\/strong><\/td><td><strong>Terapeutick\u00e9 ciele<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Klasick\u00e1 doplnkov\u00e1 trasa<\/td><td>C1q, C3, C5, MAC (C5b-9)<\/td><td>Priama l\u00fdza oligodendrocytov<\/td><td>Inhib\u00edtory C5 (ekulizumab), inhib\u00edtory C3<\/td><\/tr><tr><td>Cesta Fc\u03b3R (ADCC\/ADCP)<\/td><td>Fc\u03b3RI\/II\/III, NK bunky, makrof\u00e1gy<\/td><td>Cytotoxicita, fagocyt\u00f3za, potenci\u00e1cia T-buniek<\/td><td>Inhib\u00edtory FcRn (degrad\u00e1cia IgG), blok\u00e1da FcR<\/td><\/tr><tr><td>IL-6\/JAK-STAT3<\/td><td>IL-6, IL-6R\u03b1, gp130, JAK1\/2, STAT3, ROR\u03b3t<\/td><td>diferenci\u00e1cia Th17, dozrievanie B-buniek, produkcia IgG<\/td><td>Anti-IL-6R (tocilizumab, satralizumab)<\/td><\/tr><tr><td>PI3K\/AKT\/MAPK (B bunky)<\/td><td>BTK, PI3K, AKT, ERK, NFAT<\/td><td>aktiv\u00e1cia B-buniek, dozrievanie plazmatick\u00fdch buniek<\/td><td>Inhib\u00edtory BTK (ibrutinib, tolebrutinib)<\/td><\/tr><tr><td>Sie\u0165 cytok\u00ednov Th17<\/td><td>IL-17, IL-21, IL-22, GM-CSF, CXCL13<\/td><td>Po\u0161kodenie BBB, n\u00e1bor leukocytov, demyeliniz\u00e1cia<\/td><td>Anti-IL-17, Anti-IL-21<\/td><\/tr><tr><td>Recykl\u00e1cia FcRn-IgG<\/td><td>FcRn (novorodeneck\u00fd Fc receptor)<\/td><td>Pred\u013a\u017een\u00fd pol\u010das rozpadu IgG<\/td><td>Anti-FcRn (rozanolixizumab)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Relevante_Rezeptoren_und_Zielmolekule\"><\/span>Relevantn\u00e9 receptory a cie\u013eov\u00e9 molekuly<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOG_selbst_als_Zielstruktur_kein_klassischer_Rezeptor\"><\/span>samotn\u00fd MOG ako cie\u013eov\u00e1 \u0161trukt\u00fara (nie klasick\u00fd receptor)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">V pr\u00edpade MOGAD prote\u00edn MOG p\u00f4sob\u00ed ako antig\u00e9n, nie ako sign\u00e1lny receptor. Napriek tomu s\u00fa tieto interakcie patofyziologicky v\u00fdznamn\u00e9:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>V\u00e4zba C1q<\/strong><br>MOG m\u00f4\u017ee fyziologicky viaza\u0165 C1q, \u010do vedie k aktiv\u00e1cii komplementu v pr\u00edpade patologick\u00e9ho pokrytia protil\u00e1tkami<\/li>\n\n\n\n<li><strong>DC-SIGN (CD209)<\/strong><br>Lekt\u00ednov\u00fd receptor na dendritick\u00fdch bunk\u00e1ch; m\u00f4\u017ee viaza\u0165 MOG a prispieva\u0165 k prezent\u00e1cii antig\u00e9nu<\/li>\n\n\n\n<li><strong>Receptor v\u00edrusu rubeoly<\/strong>_<br>MOG sl\u00fa\u017ei ako vstupn\u00e1 molekula pre v\u00edrusy rubeoly, \u010do by mohlo vysvet\u013eova\u0165 postinfek\u010dn\u00fa ADEM u det\u00ed<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Fc%CE%B3-Rezeptoren_Fc%CE%B3R\"><\/span>Receptory Fc\u03b3 (Fc\u03b3R)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Receptory Fc\u03b3 na imunitn\u00fdch bunk\u00e1ch s\u00fa \u00fastredn\u00fdmi efektormi po\u0161kodenia sprostredkovan\u00e9ho IgG1:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fc\u03b3RI (CD64)<\/strong><br>Vysok\u00e1 afinita, na makrof\u00e1goch a dendritick\u00fdch bunk\u00e1ch; sprostredkovanie ADCP a prezent\u00e1cie antig\u00e9nu<\/li>\n\n\n\n<li><strong>Fc\u03b3RIII (CD16)<\/strong><br>N\u00edzka afinita, na NK bunk\u00e1ch; hlavn\u00fd medi\u00e1tor ADCC proti oligodendrocytom s opsonizovan\u00fdm MOG<\/li>\n\n\n\n<li><strong>Fc\u03b3RIIA\/B (CD32A\/B)<\/strong><br>Aktiv\u00e1cia alebo inhib\u00edcia; modul\u00e1cia aktiv\u00e1cie B-buniek a fagocyt\u00f3zy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Neonataler_Fc-Rezeptor_FcRn\"><\/span>Novorodeneck\u00fd Fc receptor (FcRn)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">FcRn (komplex \u03b22m\/FcRn-\u03b1) je zodpovedn\u00fd za vn\u00fatrobunkov\u00fa recykl\u00e1ciu protil\u00e1tok IgG. Via\u017ee IgG v acidifikovan\u00fdch endoz\u00f3moch (pH 6,0) a zabra\u0148uje jeho lyzozom\u00e1lnej degrad\u00e1cii, \u010d\u00edm predl\u017euje pol\u010das rozpadu IgG na pribli\u017ene 21 dn\u00ed.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>V MOGAD sp\u00f4sobuje FcRn trval\u00fa cirkul\u00e1ciu patog\u00e9nneho MOG-IgG1<\/li>\n\n\n\n<li>Terapeutick\u00e1 blok\u00e1da v d\u00f4sledku <em>Rozanolixizumab<\/em> (anti-FcRn IgG4): Vyn\u00fati lyzozom\u00e1lnu degrad\u00e1ciu IgG a zn\u00ed\u017ei plazmatick\u00fd IgG o ~ 50%<\/li>\n\n\n\n<li>Expresia FcRn - epitelov\u00e9 bunky, endotelov\u00e9 bunky, monocyty, hepatocyty<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"IL-6-Rezeptor_IL-6R%CE%B1_gp130\"><\/span>Receptor IL-6 (IL-6R\u03b1 \/ gp130)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Receptor IL-6 sa sklad\u00e1 z \u03b1-podjednotky via\u017eucej ligand (IL-6R\u03b1, CD126) a signaliza\u010dn\u00e9ho ko-receptora gp130 (IL-6R\u03b2, CD130). Dva sp\u00f4soby signaliz\u00e1cie:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Klasick\u00e1 signaliz\u00e1cia<\/strong><br>IL-6R\u03b1 viazan\u00fd na membr\u00e1nu na T-bunk\u00e1ch, B-bunk\u00e1ch, monocytoch \u2192 komplex IL-6\/IL-6R\u03b1\/gp130 \u2192 JAK1\/2 \u2192 STAT3, STAT1, MAPK, PI3K\/AKT<\/li>\n\n\n\n<li><strong>Trans signaliz\u00e1cia<\/strong><br>Rozpustn\u00fd IL-6R\u03b1 (sIL-6R) via\u017ee IL-6 a aktivuje gp130 aj na bunk\u00e1ch bez membr\u00e1novo viazan\u00e9ho IL-6R\u03b1 (napr. endotelov\u00e9 bunky BBB)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Relevantn\u00e9 n\u00e1sledn\u00e9 \u00fa\u010dinky: (Th17), Bcl-6 (Tfh a germin\u00e1lne centr\u00e1), Blimp-1 (plazmatick\u00e9 bunky), supresia FoxP3 (Treg).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"T-Zell-Rezeptor_TCR_und_Kostimulationsmolekule\"><\/span>T-bunkov\u00fd receptor (TCR) a kostimula\u010dn\u00e9 molekuly<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Komplex peptidov TCR\/MHC-II-MOG<\/strong><br>Centr\u00e1lna aktiva\u010dn\u00e1 os pre MOG \u0161pecifick\u00e9 CD4+ T bunky<\/li>\n\n\n\n<li><strong>CD28\/B7<\/strong><br>Kostimul\u00e1cia po\u010das aktiv\u00e1cie T-buniek<\/li>\n\n\n\n<li><strong>Os CCR6\/CCL20<\/strong><br>CCR6 na bunk\u00e1ch Th17 via\u017ee CCL20 v choroid\u00e1lnom plexe \u2192 vstup do CNS<\/li>\n\n\n\n<li><strong>CXCR3\/CXCL10<\/strong><br>Chemotaxia Th1 buniek v oblastiach z\u00e1palu<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Komplementrezeptoren\"><\/span>Receptory komplementu<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>C1qR<\/strong><br>Sprostredk\u00fava v\u00e4zbu C1q na imunitn\u00e9 komplexy na membr\u00e1nach oligodendrocytov<\/li>\n\n\n\n<li><strong>C3aR <\/strong>a<strong> C5aR1 (CD88)<\/strong><br>Anafylatox\u00ednov\u00e9 receptory na mikrogliach\/makrof\u00e1goch \u2192 Proz\u00e1palov\u00e1 aktiv\u00e1cia<\/li>\n\n\n\n<li><strong>Regul\u00e1tory komplementu na oligodendrocytoch<\/strong><br>CR1 (CD35), MCP (CD46), HRF (CD59) s\u00fa slabo exprimovan\u00e9 na oligodendrocytoch, \u010do ich rob\u00ed n\u00e1chylnej\u0161\u00edmi na po\u0161kodenie komplementom ako napr. astrocyty<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Histopathologie_und_ZNS-Lasionsmuster\"><\/span>Histopatol\u00f3gia a vzor l\u00e9zie CNS<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">L\u00e9zie MOGAD sa histopatologicky z\u00e1sadne l\u00ed\u0161ia od SM a NMOSD:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Periven\u00f3zna demyeliniz\u00e1cia<\/strong><br>L\u00e9zie sa tvoria koncentricky okolo mal\u00fdch \u017e\u00edl (periven\u00f3zny vzor), nie periaxi\u00e1lne ako pri SM. Na MRI ch\u00fdba typick\u00e9 \u201aznamenie centr\u00e1lnych \u017e\u00edl\u2018 pre SM<\/li>\n\n\n\n<li><strong>Infiltr\u00e1t CD4+ T-buniek<\/strong><br>Dominantn\u00fdm z\u00e1palov\u00fdm bunkov\u00fdm obrazom s\u00fa CD4+ T-bunky a makrof\u00e1gy, menej neutrofilov a takmer \u017eiadne eozinofiln\u00e9 granulocyty (na rozdiel od AQP4+ NMOSD)<\/li>\n\n\n\n<li><strong>Po\u0161kodenie oligodendrocytov<\/strong> (prim\u00e1rne)<br>Na rozdiel od NMOSD, kde s\u00fa prim\u00e1rne po\u0161koden\u00e9 astrocyty, je MOGAD charakterizovan\u00e1 degener\u00e1ciou oligodendrocytov<\/li>\n\n\n\n<li><strong>Ukladanie C9neo<\/strong><br>Detekcia MAC (termin\u00e1lneho komplexu komplementu) v l\u00e9zi\u00e1ch, aj ke\u010f slab\u0161ia ako pri NMOSD<\/li>\n\n\n\n<li><strong>Relat\u00edvne zachovanie ax\u00f3nov<\/strong><br>Pri ak\u00fatnych z\u00e1chvatoch je axon\u00e1lne po\u0161kodenie \u010dasto menej z\u00e1va\u017en\u00e9 ako pri SM, \u010do vysvet\u013euje \u010dasto dobr\u00e9 klinick\u00e9 zotavenie.<\/li>\n\n\n\n<li><strong>Kortik\u00e1lne l\u00e9zie<\/strong><br>Leptomeninge\u00e1lny z\u00e1pal a kortik\u00e1lna demyeliniz\u00e1cia (\u010dast\u00e9 pri variante ADEM)<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Klinische_Manifestationen_und_Phanotypen\"><\/span>Klinick\u00e9 prejavy a fenotypy<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD je klinicky heterog\u00e9nny. D\u00f4le\u017eit\u00e9 fenotypy:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Fenotyp<\/strong><\/td><td><strong>Frekvencia<\/strong><\/td><td><strong>Klinick\u00e9 vlastnosti<\/strong><\/td><td><strong>\u0160peciality MRI<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Optick\u00e1 neurit\u00edda (ON)<\/td><td>Najbe\u017enej\u0161ie (pribli\u017ene 50%)<\/td><td>\u010casto obojstrann\u00e9, strata zraku, retrobulb\u00e1rne, bolestiv\u00e9 pohyby o\u010d\u00ed. pohyby o\u010d\u00ed<\/td><td>Dlh\u00e9 postihnutie zrakov\u00e9ho nervu, hromadenie kontrastnej l\u00e1tky v perinerve<\/td><\/tr><tr><td>Prie\u010dna myelit\u00edda<\/td><td>Pribli\u017ene 30%<\/td><td>Longitudin\u00e1lna myelit\u00edda (LETM), senzorick\u00e9\/motorick\u00e9 poruchy, poruchy mo\u010dov\u00e9ho mech\u00fara<\/td><td>Pozd\u013a\u017ene T2 l\u00e9zie, H2 syndr\u00f3m (\u201a\u0161o\u0161ovkovit\u00fd\u2018)<\/td><\/tr><tr><td>ADEM<\/td><td>Naj\u010dastej\u0161ie prejavy u det\u00ed<\/td><td>Encefalopatia, polyfok\u00e1lne neurologick\u00e9 deficity deficity<\/td><td>Bilater\u00e1lne, ve\u013ekoobjemov\u00e9 T2 l\u00e9zie, tie\u017e baz\u00e1lne gangli\u00e1<\/td><\/tr><tr><td>Encefalit\u00edda mozgov\u00e9ho kme\u0148a<\/td><td>Pribli\u017ene 15%<\/td><td>Diplopia, ataxia, area postrema syndr\u00f3m (\u0161tik\u00fatka, vracanie)<\/td><td>Mozgov\u00fd kme\u0148 \/ mozo\u010dkov\u00e9 T2 l\u00e9zie<\/td><\/tr><tr><td>Kortik\u00e1lna encefalit\u00edda<\/td><td>Zriedkavej\u0161ie<\/td><td>Epileptick\u00e9 z\u00e1chvaty, zm\u00e4tenos\u0165<\/td><td>Zmeny signaliz\u00e1cie kortik\u00e1lnej FLAIR<\/td><\/tr><tr><td>CRION<\/td><td>Zriedkavej\u0161ie<\/td><td>Chronick\u00fd recidivuj\u00faci z\u00e1pal. optick\u00e1 neuropatia<\/td><td>Trval\u00e9 po\u0161kodenie zrakov\u00e9ho nervu<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Diagnostik\"><\/span>Diagnostika<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">Diagnostick\u00e9 krit\u00e9ri\u00e1 (Banwell et al, <em>Lancet Neurology<\/em> 2023): <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">(1) Detekcia MOG-IgG v s\u00e9re alebo mozgovomiechovom moku pomocou bunkov\u00e9ho testu (CBA)<br>(2) vhodn\u00fd klinick\u00fd fenotyp<br>(3) Vyl\u00fa\u010denie alternat\u00edvnych diagn\u00f3z.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bunkov\u00fd imunofluorescen\u010dn\u00fd test (CBA)<\/strong><br>s prirodzene zlo\u017een\u00fdm, membr\u00e1novo viazan\u00fdm MOG (bunky HEK293 transfekovan\u00e9 \u013eudsk\u00fdm MOG); detekuje epitopy z\u00e1visl\u00e9 od konform\u00e1cie<\/li>\n\n\n\n<li><strong>ELISA a line\u00e1rne\/prieskumn\u00e9 bloty<\/strong><br>Nespo\u013eahliv\u00e9 pre MOGAD, ke\u010f\u017ee sa rozpozn\u00e1vaj\u00fa line\u00e1rne epitopy<\/li>\n\n\n\n<li><strong>Podtriedy IgG<\/strong><br>Predov\u0161etk\u00fdm IgG1; pr\u00edle\u017eitostne IgG2, IgG3, IgG4. V\u00fdlu\u010dn\u00e1 pozitivita IgG3 je diagnostick\u00fdm \u00faskal\u00edm (Jarius 2024)<\/li>\n\n\n\n<li><strong>Titrov\u00e1 kinetika<\/strong><br>Trvalo vysok\u00e9 titre koreluj\u00fa s rizikom relapsu; pri monof\u00e1zickom priebehu \u010dasto klesaj\u00fa<\/li>\n\n\n\n<li><strong>Alkohol<\/strong><br>Mo\u017en\u00e1 pleocyt\u00f3za; oligoklon\u00e1lne p\u00e1sy zriedkav\u00e9 (&lt;10 %), intratek\u00e1lna synt\u00e9za IgG zriedkav\u00e1<\/li>\n\n\n\n<li><strong>Biomarkery<\/strong><br>sNfL (\u013eahk\u00fd re\u0165azec neurofilament v s\u00e9re) ako marker aktivity ochorenia; sGFAP (gliov\u00fd fibril\u00e1rny kysl\u00fd prote\u00edn) ako marker astrocyt\u00e1rneho postihnutia<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Therapeutische_Strategien\"><\/span>Terapeutick\u00e9 strat\u00e9gie<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Akuttherapie_Schubbehandlung\"><\/span>Ak\u00fatna lie\u010dba (lie\u010dba relapsu)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\u0160tandardn\u00e1 lie\u010dba relapsu MOGAD:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vysoko d\u00e1vkovan\u00e9 <em>Metylprednizol\u00f3n<\/em> (HDMP)<\/strong><br>1000 mg i.v. denne po\u010das 5 dn\u00ed - prv\u00e1 l\u00ednia<\/li>\n\n\n\n<li><em><strong>Plazmafer\u00e9za \/ imunoadsorpcia<\/strong><\/em><br>V pr\u00edpade nedostato\u010dnej odpovede HDMP; odstra\u0148uje MOG-IgG z plazmy; 5-7 cyklov (retrospekt\u00edvne \u00fadaje ukazuj\u00fa \u00fa\u010dinnos\u0165 v pribli\u017ene 50-70% pr\u00edpadoch)<\/li>\n\n\n\n<li><strong><em>Intraven\u00f3zne imunoglobul\u00edny<\/em> (IVIG)<\/strong><br>2 g\/kg po\u010das 5 dn\u00ed; pri absencii odpovede na HDMP a ako mo\u017enos\u0165 po plazmafer\u00e9ze; pravdepodobne \u00fa\u010dinn\u00fd prostredn\u00edctvom satur\u00e1cie FcRn a konkurencie Fc\u03b3R<\/li>\n\n\n\n<li><strong>Vysadenie kortikosteroidov<\/strong><br>Obzvl\u00e1\u0161\u0165 d\u00f4le\u017eit\u00e9 pri MOGAD (\u010dast\u00e1 z\u00e1vislos\u0165 od steroidov) - r\u00fdchle zn\u00ed\u017eenie m\u00f4\u017ee vyvola\u0165 rebound epiz\u00f3dy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Prophylaktische_Langzeittherapie\"><\/span>Profylaktick\u00e1 dlhodob\u00e1 lie\u010dba<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">(off-label, \u017eiadny registrovan\u00fd pr\u00edpravok - stav 2026)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Indik\u00e1cia dlhodobej lie\u010dby je individu\u00e1lna - nie v\u0161etci pacienti ju potrebuj\u00fa. Faktory: po\u010det relapsov, z\u00e1va\u017enos\u0165 relapsov, pretrv\u00e1vaj\u00face titre MOG-IgG, fenotypov\u00e9 rizikov\u00e9 faktory.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>L\u00e1tka<\/strong><\/td><td><strong>Mechanizmus \u00fa\u010dinku<\/strong><\/td><td><strong>Situ\u00e1cia s \u00fadajmi<\/strong><\/td><td><strong>\u00darove\u0148 d\u00f4kazov<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Azatiopr\u00edn<\/td><td>Blok\u00e1da synt\u00e9zy pur\u00ednov (z\u00e1visl\u00e1 od TPMT); inhibuje prolifer\u00e1ciu T a B buniek<\/td><td>Retrospekt\u00edvne \u0161t\u00fadie; prebieha n\u00e1rodn\u00e1 RCT (Franc\u00fazsko, \u0161t\u00fadia TOMATO)<\/td><td>IIb-III (off-label)<\/td><\/tr><tr><td>Mykofenol\u00e1t mofetil (MMF)<\/td><td>Inhib\u00edtor inoz\u00ednmonofosf\u00e1tdehydrogen\u00e1zy; inhibuje prolifer\u00e1ciu lymfocytov<\/td><td>S\u00e9rie pr\u00edpadov; pravdepodobne \u00fa\u010dinn\u00e1, ni\u017e\u0161ia prevencia relapsu ako rituximab<\/td><td>III (off-label)<\/td><\/tr><tr><td>Rituximab<\/td><td>Anti-CD20 \u2192 depl\u00e9cia B-buniek; inhibuje produkciu MOG-IgG<\/td><td>Najv\u00e4\u010d\u0161ia retrospekt\u00edvna kohorta; \u00fa\u010dinn\u00e9, nie pre ka\u017ed\u00e9ho; zv\u00fd\u0161en\u00e9 riziko infekcie<\/td><td>IIb (off-label)<\/td><\/tr><tr><td>Tocilizumab<\/td><td>Anti-IL-6R\u03b1 (iv); blokuje sign\u00e1lnu dr\u00e1hu IL-6 (JAK\/STAT3); inhibuje Th17\/plazmatick\u00e9 bunky<\/td><td>Pozit\u00edvne retrospekt\u00edvne \u00fadaje; v\u00fdsledky RCT pre NMOSD pozit\u00edvne (TANGO)<\/td><td>IIb (off-label)<\/td><\/tr><tr><td>IVIG (iv\/subkut\u00e1nne)<\/td><td>Nas\u00fdtenie Fc receptora; neutraliz\u00e1cia MOG-IgG; nas\u00fdtenie FcRn<\/td><td>Pozit\u00edvne retrospekt\u00edvne \u00fadaje; mo\u017enos\u0165 pre plodnos\u0165, tehotenstvo, infekciu<\/td><td>IIb (off-label)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Klinische_Studien_%E2%80%93_2024%E2%80%932026\"><\/span>Klinick\u00e9 \u0161t\u00fadie - 2024-2026<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Prv\u00fdkr\u00e1t prebieha nieko\u013eko randomizovan\u00fdch, placebom kontrolovan\u00fdch \u0161t\u00fadi\u00ed f\u00e1zy 3 pre MOGAD, ktor\u00e9 by mali poskytn\u00fa\u0165 d\u00f4kazy triedy I:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>\u0160t\u00fadia<\/strong><\/td><td><strong>L\u00e1tka<\/strong><\/td><td><strong>Mechanizmus<\/strong><\/td><td><strong>Cie\u013eov\u00e1 skupina<\/strong><\/td><td><strong>Stav<\/strong><\/td><\/tr><\/thead><tbody><tr><td>cosMOG<\/td><td>Rozanolixizumab (UCB7665)<\/td><td>Anti-FcRn IgG4-mAb: blokuje recykl\u00e1ciu IgG \u2192 ur\u00fdch\u013euje degrad\u00e1ciu IgG, zni\u017euje titer MOG IgG ~50 %<\/td><td>Dospel\u00ed (\u2265 18 rokov), relaps, \u2265 1 relaps\/12 mesiacov<\/td><td>F\u00e1za 3, medzin\u00e1rodn\u00e1; v\u00f4bec prv\u00e1 \u0161t\u00fadia f\u00e1zy 3 MOGAD<\/td><\/tr><tr><td>METEOROID<\/td><td>Satralizumab (anti-IL-6R sc.)<\/td><td>Anti-IL-6R (subkut\u00e1nne); inhibuje JAK\/STAT3 \u2192 diferenci\u00e1cia Th17, dozrievanie B-buniek, produkcia IgG<\/td><td>Dospel\u00ed + dospievaj\u00faci (\u2265 12 rokov); relaps, ktor\u00e9mu predch\u00e1dzal \u2265 1 relaps<\/td><td>F\u00e1za 3, medzin\u00e1rodn\u00e1, prebieha<\/td><\/tr><tr><td>TOMATO<\/td><td>Azatiopr\u00edn<\/td><td>Inhib\u00edcia synt\u00e9zy pur\u00ednov; v\u0161eobecne imunosupres\u00edvny<\/td><td>Franc\u00fazska multicentrick\u00e1 \u0161t\u00fadia; dospel\u00ed s MOGAD<\/td><td>N\u00e1rodn\u00e1 RCT, f\u00e1za 3<\/td><\/tr><tr><td>MOGwAI<\/td><td>Nie je \u0161pecifikovan\u00e9 (pozorovanie)<\/td><td>\u0160t\u00fadia biomarkerov: valid\u00e1cia titra MOG-IgG, sNfL, sGFAP, sCD83 ako markerov progresie<\/td><td>Medzin\u00e1rodn\u00e1 kohortov\u00e1 \u0161t\u00fadia<\/td><td>Priebe\u017ene<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Neue_und_zukunftige_Therapiekonzepte\"><\/span>Nov\u00e9 a bud\u00face koncepcie lie\u010dby<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Na z\u00e1klade molekul\u00e1rnych zisten\u00ed z posledn\u00fdch rokov sa diskutuje o nasleduj\u00facich pr\u00edstupoch k MOGAD:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"BTK-Inhibitoren_Bruton-Tyrosin-Kinase\"><\/span>Inhib\u00edtory BTK (Brutonova tyroz\u00ednkin\u00e1za)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">BTK je centr\u00e1lnou kin\u00e1zou v signaliza\u010dnej kask\u00e1de B-bunkov\u00e9ho receptora (PI3K\/AKT\/MAPK). <strong><em>Tolebrutinib<\/em><\/strong> a in\u00e9 inhib\u00edtory BTK s\u00fa vo v\u00fdskume SM a NMOSD; klinick\u00e9 sk\u00fa\u0161ky MOGAD sa e\u0161te len pripravuj\u00fa. Peror\u00e1lna aplik\u00e1cia by bola v\u00fdhodou. Inhib\u00edcia aktiv\u00e1cie B-buniek aj myeloidn\u00fdch buniek (mikroglia-BTK).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Toleranzinduktion_MOG-Tolerisierung\"><\/span>Navodenie tolerancie (tolerancia MOG)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">S\u013eubnou koncepciou je indukcia antig\u00e9novo \u0161pecifickej tolerancie (napr. prostredn\u00edctvom peptidov MOG alebo pr\u00edstupov na b\u00e1ze nano\u010dast\u00edc). Na str\u00e1nke <strong><em>Charitat\u00edvna nad\u00e1cia Guthy-Jackson<\/em><\/strong> Podporuje v\u00fdskum lie\u010debn\u00fdch postupov. V\u00fdhoda: \u017diadna glob\u00e1lna imunosupresia, <strong>Selekt\u00edvna elimin\u00e1cia autoreaktivity MOG<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Komplementinhibitoren\"><\/span>Inhib\u00edtory komplementu<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ke\u010f\u017ee aktiv\u00e1cia komplementu (C3a, C5a, MAC) je zistite\u013en\u00e1 v l\u00e9zi\u00e1ch MOGAD, bolo by <strong><em>Eculizumab<\/em> (Anti-C5)<\/strong> alebo inhib\u00edtor C3 je teoreticky \u00fa\u010dinn\u00fd. Ke\u010f\u017ee sa v\u0161ak komplex MAC (C5b-9) tvor\u00ed v ove\u013ea men\u0161ej miere v MOGAD ako v NMOSD (kde <em>Eculizumab<\/em> je povolen\u00e9), klinick\u00fd v\u00fdznam je neist\u00fd.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Anti-Neonatal-Fc-Rezeptor-Strategien\"><\/span>Strat\u00e9gie proti neonat\u00e1lnemu Fc receptoru<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Okrem <em>Rozanolixizumab<\/em> bude tie\u017e <strong><em>Efgartigimod<\/em><\/strong> (IgG-Fc fragment, ktor\u00fd kompetit\u00edvne blokuje FcRn) pre in\u00e9 ochorenia sprostredkovan\u00e9 IgG. Ke\u010f\u017ee patomechanizmus blok\u00e1dy FcRn priamo zni\u017euje hladinu MOG-IgG, ide o mimoriadne cielen\u00fd pr\u00edstup.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Autologe_hamatopoetische_Stammzelltransplantation_aHSCT\"><\/span>Autol\u00f3gna transplant\u00e1cia krvotvorn\u00fdch kme\u0148ov\u00fdch buniek (aHSCT)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">V pr\u00edpade \u0165a\u017ek\u00fdch, na lie\u010dbu refrakt\u00e9rnych priebehov je aHSCT potenci\u00e1lne lie\u010debn\u00fdm konceptom: hlbok\u00e1 imunoabl\u00e1cia a rekon\u0161tit\u00facia imunitn\u00e9ho syst\u00e9mu by mohli eliminova\u0165 autoreakt\u00edvne klony T a B buniek. Pre MOGAD je k dispoz\u00edcii ve\u013emi m\u00e1lo \u00fadajov; pou\u017eitie len v \u0161pecializovan\u00fdch centr\u00e1ch.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Biomarker_und_Verlaufsmonitoring\"><\/span>Biomarkery a n\u00e1sledn\u00e9 monitorovanie<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">Cie\u013eom s\u00fa\u010dasn\u00e9ho v\u00fdskumu je rozhodovanie o lie\u010dbe na z\u00e1klade biomarkerov:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MOG-IgG titer (s\u00e9rum)<\/strong><br>Perzistencia koreluje s rizikom relapsu; pri monof\u00e1zickom priebehu \u010dasto spont\u00e1nny pokles titra; spolurozhoduje rozhodnutie o terapii<\/li>\n\n\n\n<li><strong>S\u00e9rov\u00e9 neurofilamentov\u00e9 svetlo (sNfL)<\/strong><br>Marker axon\u00e1lneho po\u0161kodenia; zv\u00fd\u0161en\u00fd po\u010das relapsu; normaliz\u00e1cia ako marker odpovede na lie\u010dbu<\/li>\n\n\n\n<li><strong>S\u00e9rov\u00fd GFAP (sGFAP)<\/strong><br>Astrocyt\u00e1rna aktiv\u00e1cia; ni\u017e\u0161ia pri MOGAD ako pri NMOSD; m\u00f4\u017ee poskytn\u00fa\u0165 dopl\u0148uj\u00face inform\u00e1cie<\/li>\n\n\n\n<li><strong>sCD83<\/strong><br>Nov\u00fd kandid\u00e1tsky biomarker (v procese valid\u00e1cie); pravdepodobne marker aktiv\u00e1cie dendritick\u00fdch buniek a imunitnej aktivity<\/li>\n\n\n\n<li><strong>Po\u010det buniek a bielkov\u00edn v mozgovomiechovom moku<\/strong><br>Pleocyt\u00f3za po\u010das epiz\u00f3d \u0165ahu; normaliz\u00e1cia po lie\u010dbe<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Prognose_und_Besonderheiten\"><\/span>Predpove\u010f a \u0161peci\u00e1lne funkcie<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">V porovnan\u00ed s AQP4+ NMOSD m\u00e1 MOGAD tendenciu vykazova\u0165 <strong>Priaznivej\u0161ia predpove\u010f<\/strong>, najm\u00e4 lep\u0161ie zotavenie zraku po zapnut\u00ed. D\u00f4le\u017eit\u00e9 s\u00fa v\u0161ak tieto aspekty:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Monof\u00e1zov\u00e1 progresia<\/strong><br>Pribli\u017ene 50% pacientov; \u010dasto spont\u00e1nny pokles titra; nemus\u00ed by\u0165 potrebn\u00e1 dlhodob\u00e1 lie\u010dba<\/li>\n\n\n\n<li><strong>Postup v tvare \u0165ahu<\/strong><br>Pribli\u017ene 50%; pretrv\u00e1va vy\u0161\u0161\u00ed titer; je mo\u017en\u00e9 kumulat\u00edvne narastanie postihnutia, ale pomal\u0161ie ako pri NMOSD<\/li>\n\n\n\n<li><strong>\u017diadny progres\u00edvny kurz<\/strong><br>Na rozdiel od SM nebola op\u00edsan\u00e1 postupn\u00e1 progresia bez relapsov<\/li>\n\n\n\n<li><strong>Citlivos\u0165 na steroidy a z\u00e1vislos\u0165 od steroidov<\/strong><br>Mnoh\u00ed pacienti v\u0161ak na kortikosteroidy reaguj\u00fa ve\u013emi dobre: r\u00fdchle zn\u00ed\u017eenie d\u00e1vky \u010dasto vyvol\u00e1va relapsy<\/li>\n\n\n\n<li><strong>\u0160peci\u00e1lna pediatrick\u00e1 funkcia<\/strong><br>ADEM naj\u010dastej\u0161\u00ed po\u010diato\u010dn\u00fd prejav u det\u00ed (&lt;10 rokov); progn\u00f3za je \u010dasto dobr\u00e1, ale treba si uvedomi\u0165 riziko recid\u00edvy<\/li>\n\n\n\n<li><strong>Tehotenstvo: nedostatok \u00fadajov<\/strong><br>Po\u010das tehotenstva nie je v\u0161eobecne zv\u00fd\u0161en\u00e9 riziko recid\u00edvy, ale po p\u00f4rode m\u00f4\u017ee by\u0165 rizikov\u00fdm faktorom (podobne ako pri SM).<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Zusammenfassung_und_Ausblick\"><\/span>Zhrnutie a v\u00fdh\u013ead<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD je nez\u00e1visl\u00e9 autoimunitn\u00e9 ochorenie CNS sprostredkovan\u00e9 protil\u00e1tkami, ktor\u00e9 sa vyzna\u010duje t\u00fdmito hlavn\u00fdmi znakmi:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Prote\u00edn MOG na vonkaj\u0161ej strane oligodendrocytov a myel\u00ednov\u00fdch po\u0161iev je cie\u013eov\u00fdm antig\u00e9nom<\/li>\n\n\n\n<li>Patog\u00e9nne autoprotil\u00e1tky MOG-IgG1 po\u0161kodzuj\u00fa myel\u00edn prostredn\u00edctvom dvoch paraleln\u00fdch efektorov\u00fdch dr\u00e1h: aktiv\u00e1cia komplementu (CDC, pribli\u017ene 50%) a v\u00e4zba Fc\u03b3R (ADCC\/ADCP, pribli\u017ene 50%)<\/li>\n\n\n\n<li>Okrem toho protil\u00e1tky posil\u0148uj\u00fa aktiv\u00e1ciu T-buniek prostredn\u00edctvom mechanizmov Fc\u03b3R<\/li>\n\n\n\n<li>Sign\u00e1lna dr\u00e1ha IL-6\/JAK\/STAT3 podporuje diferenci\u00e1ciu Th17 a dozrievanie plazmatick\u00fdch buniek a je k\u013e\u00fa\u010dov\u00fdm terapeutick\u00fdm cie\u013eom<\/li>\n\n\n\n<li>V s\u00fa\u010dasnosti neexistuje \u017eiadna schv\u00e1len\u00e1 terapia (od febru\u00e1ra 2026); prebiehaj\u00fa prv\u00e9 RCT f\u00e1zy 3 (cosMOG s rozanolixizumabom, METEOROID so satralizumabom)<\/li>\n\n\n\n<li>Terapia sa pos\u00fava smerom k strat\u00e9gi\u00e1m prisp\u00f4soben\u00fdm riziku a zalo\u017een\u00fdm na biomarkeroch<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Najv\u00fdznamnej\u0161\u00edm pokrokom vo v\u00fdskume v posledn\u00fdch rokoch bolo presn\u00e9 dek\u00f3dovanie efektorov\u00fdch mechanizmov (komplement vs. FcR dr\u00e1ha) v\u00fdskumn\u00fdmi skupinami, ako napr. <strong>Meinl, Mader, Kawakami (LMU Mn\u00edchov)<\/strong>, \u010do m\u00e1 priamy vplyv na v\u00fdvoj terapie: Optim\u00e1lny terapeutick\u00fd pr\u00edstup sa mus\u00ed zamera\u0165 na produkciu IgG (anti-CD20, inhib\u00edtory FcRn), ako aj na efektorov\u00e9 mechanizmy (komplement, Fc\u03b3R) a os Th17\/IL-6.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Strat\u00e9gie indukcie tolerancie a inhib\u00edtory BTK predstavuj\u00fa bud\u00face, mechanisticky zalo\u017een\u00e9 terapeutick\u00e9 princ\u00edpy, ktor\u00e9 sa pravdepodobne bud\u00fa klinicky sk\u00fa\u0161a\u0165 v nasleduj\u00facich rokoch.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Atherischer_Ole_%E2%80%93_Wirkstoffe_nach_Signalwegen_geordnet\"><\/span>Esenci\u00e1lne oleje - \u00fa\u010dinn\u00e9 l\u00e1tky zoraden\u00e9 pod\u013ea sign\u00e1lnych dr\u00e1h<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\u00da\u010dinn\u00e9 l\u00e1tky mo\u017eno zoskupi\u0165 pod\u013ea ich miesta p\u00f4sobenia v patofyziol\u00f3gii MOGAD. Je to ve\u013emi d\u00f4le\u017eit\u00e9, preto\u017ee MOGAD m\u00e1 tri hlavn\u00e9 osi: <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Th17\/IL-6<\/strong><\/li>\n\n\n\n<li><strong>Komplementov\u00fd syst\u00e9m\/oligodendrocytov\u00e1 ochrana<\/strong><\/li>\n\n\n\n<li><strong>Remyeliniz\u00e1cia\/diferenci\u00e1cia OPC<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Weihrauch_Boswellia_serrata_%E2%80%93_AKBA_und_Incensolacetat\"><\/span>Kadidlo (Boswellia serrata) - AKBA a incensol acet\u00e1t<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Pod\u013ea BCP ide o vedecky najviac podlo\u017een\u00fd kandid\u00e1t na MOGAD, ktor\u00fd je v\u00fdnimo\u010dn\u00fd svoj\u00edm rozsahom \u00fa\u010dinkov.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>AKBA (kyselina 3-O-acetyl-11-keto-\u03b2-boswellov\u00e1)<\/strong> je hlavnou \u00fa\u010dinnou l\u00e1tkou. AKBA m\u00e1 viacer\u00e9 fyziologick\u00e9 \u00fa\u010dinky vr\u00e1tane protiinfek\u010dn\u00fdch, protin\u00e1dorov\u00fdch a antioxida\u010dn\u00fdch \u00fa\u010dinkov, ako aj preuk\u00e1zan\u00e9 neuroprotekt\u00edvne \u00fa\u010dinky. Podporuje obnovu a regener\u00e1ciu nervov, chr\u00e1ni pred ischemick\u00fdm po\u0161koden\u00edm mozgu, potl\u00e1\u010da neuroz\u00e1pal a zlep\u0161uje pam\u00e4\u0165ov\u00e9 deficity. <a href=\"https:\/\/www.ean.org\/research\/resources\/neurology-updates\/detail\/complement-dependent-and-independent-pathomechanisms-of-myelin-oligodendrocyte-glycoprotein-mog-abs-implications-for-therapeutic-strategies-in-mog-antibody-associated-disease-mogad\" target=\"_blank\" rel=\"noreferrer noopener\">Eur\u00f3pska neurologick\u00e1 akad\u00e9mia<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>AKBA inhibuje STAT3<\/strong> v z\u00e1vislosti od d\u00e1vky, \u010do je k\u013e\u00fa\u010dov\u00fd mechanizmus, ke\u010f\u017ee STAT3 je hlavn\u00fdm efektorov\u00fdm transkrip\u010dn\u00fdm faktorom IL-6\/JAK sign\u00e1lnej dr\u00e1hy, ktor\u00e1 riadi diferenci\u00e1ciu Th17 a dozrievanie plazmatick\u00fdch buniek v MOGAD. Okrem toho aktiv\u00e1cia sign\u00e1lnej dr\u00e1hy Nrf2\/HO-1 prostredn\u00edctvom AKBA poskytuje smer na zn\u00ed\u017eenie oxida\u010dn\u00e9ho po\u0161kodenia, prevenciu demyeliniz\u00e1cie a podporu remyeliniz\u00e1cie. <a href=\"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.nanolett.9b02220\" target=\"_blank\" rel=\"noreferrer noopener\">Publik\u00e1cie ACS<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">AKBA p\u00f4sob\u00ed ako molekul\u00e1rny sp\u00edna\u010d, ktor\u00fd blokuje tvorbu leukotri\u00e9nov prostredn\u00edctvom alosterickej modul\u00e1cie 5-LOX a 15-LOX, ale z\u00e1rove\u0148 stimuluje tvorbu SPM (\u0161pecializovan\u00fdch proreaguj\u00facich medi\u00e1torov). T\u00fdm sa imunitn\u00e1 odpove\u010f akt\u00edvne pos\u00fava smerom k <strong>Rie\u0161enie z\u00e1palu<\/strong>, nielen ich tlmenie. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39133885\/\" target=\"_blank\" rel=\"noreferrer noopener\">PubMed<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Acet\u00e1t incenzolu<\/strong> (prchav\u00e1 zlo\u017eka kadidlov\u00e9ho esenci\u00e1lneho oleja, st\u00e1va sa BHS) aktivuje kan\u00e1ly TRPV3 v neur\u00f3noch, ako aj PPAR-\u03b3 - zlo\u017eky kadidla m\u00f4\u017eu v\u00fdznamne zn\u00ed\u017ei\u0165 IL-6, TNF-\u03b1 a GFAP (marker aktiv\u00e1cie astrocytov) v mozgu po indukovanom z\u00e1pale. <a href=\"https:\/\/www.neurology.org\/doi\/10.1212\/NXI.0000000000200293\" target=\"_blank\" rel=\"noreferrer noopener\">Neurol\u00f3gia<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>D\u00f4le\u017eit\u00e1 pozn\u00e1mka o kvalite:<\/strong> Medzi jednotliv\u00fdmi produktmi boswellie s\u00fa zna\u010dn\u00e9 rozdiely v kvalite, niektor\u00e9 produkty (napr. H15 Ayurmedica\u00ae) obsahovali v anal\u00fdzach len stopov\u00e9 mno\u017estv\u00e1 charakteristick\u00fdch boswellov\u00fdch kysel\u00edn (0,31 mg AKBA). Naopak, produkty ako BOSWELLIASAN\u00ae (7,51 mg) a Sallaki\u00ae Tablets (7,88 mg) vykazovali zna\u010dn\u00e9 mno\u017estvo AKBA a tomu zodpovedaj\u00face siln\u00e9 farmakologick\u00e9 \u00fa\u010dinky. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34358086\/\" target=\"_blank\" rel=\"noreferrer noopener\">Anal\u00fdza obsahu kyseliny boswellovej a s\u00favisiacich farmakologick\u00fdch aktiv\u00edt liekov na b\u00e1ze kadidla, ktor\u00e9 moduluj\u00fa z\u00e1pal<\/a> a <a href=\"https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2025.1530977\/full\" target=\"_blank\" rel=\"noreferrer noopener\">Hranice<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Produkt doTERRA <strong><a href=\"https:\/\/media.doterra.com\/us\/en\/pips\/frankincense-boswellic-acid-complex.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Komplex kadidlovn\u00edka s kyselinou boswellovou<\/a><\/strong> obsahuje 37,5 mg AKBA*<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Therapeutisch_relevante_AKBA-Zieldosen\"><\/span>Terapeuticky relevantn\u00e9 cie\u013eov\u00e9 d\u00e1vky AKBA<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Z klinick\u00e9ho a predklinick\u00e9ho v\u00fdskumu vypl\u00fdva nasleduj\u00faci obraz:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Cie\u013e aplik\u00e1cie<\/th><th>Denn\u00e1 d\u00e1vka AKBA<\/th><th>Zdroj<\/th><\/tr><\/thead><tbody><tr><td>Protiz\u00e1palov\u00fd (v\u0161eobecne)<\/td><td>100-200 mg<\/td><td>\u013dudsk\u00e9 \u0161t\u00fadie k\u013ab\/\u010drevo<\/td><\/tr><tr><td>Inhib\u00edcia NF-\u03baB \/ STAT3 (neuroz\u00e1pal)<\/td><td>200-400 mg<\/td><td>Zvieracie modely, bunkov\u00e9 kult\u00fary<\/td><\/tr><tr><td>Optim\u00e1lny \u00fa\u010dinok na CNS (bari\u00e9rov\u00fd priechod)<\/td><td>200-300 mg<\/td><td>Experiment\u00e1lne \u00fadaje<\/td><\/tr><tr><td>Horn\u00e1 dobre tolerovan\u00e1 denn\u00e1 d\u00e1vka<\/td><td>400-600 mg<\/td><td>\u0160t\u00fadie tolerancie<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Umrechnung_auf_375_mg_AKBA_jeKapsel\"><\/span>Konverzia na 37,5 mg AKBA na kapsulu<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Cie\u013eov\u00e1 denn\u00e1 d\u00e1vka AKBA<\/th><th>Jednotky\/de\u0148<\/th><th>Praktick\u00e1 sch\u00e9ma<\/th><\/tr><\/thead><tbody><tr><td>150 mg<\/td><td>4 jednotky<\/td><td>2 \u00d7 r\u00e1no + 2 \u00d7 ve\u010der<\/td><\/tr><tr><td>200 mg<\/td><td><strong>5-6 jednotiek<\/strong><\/td><td>3 \u00d7 r\u00e1no + 2-3 \u00d7 ve\u010der<\/td><\/tr><tr><td>300 mg<\/td><td>8 jednotiek<\/td><td>4 \u00d7 r\u00e1no + 4 \u00d7 ve\u010der<\/td><\/tr><tr><td>400 mg<\/td><td>10-11 jednotiek<\/td><td>3 \u00d7 3-4 jednotky denne<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Odpor\u00fa\u010dan\u00fd vstup:<\/strong> <strong>4 jednotky denne (= 150 mg AKBA)<\/strong>, rozdelen\u00e9 na 2 dar\u010deky.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Po 2 t\u00fd\u017ed\u0148och - ak je dobre tolerovan\u00fd - zv\u00fd\u0161te d\u00e1vku na 6 jednotiek (= 225 mg).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wichtige_Einnahmehinweise\"><\/span>D\u00f4le\u017eit\u00e9 pokyny pre pr\u00edjem<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tuk je ve\u013emi d\u00f4le\u017eit\u00fd:<\/strong> AKBA je vysoko lipofiln\u00fd, a <strong>Biologick\u00e1 dostupnos\u0165 sa zvy\u0161uje 2-3 kr\u00e1t<\/strong>, ak sa u\u017e\u00edva s mastn\u00fdm jedlom. Ide\u00e1lny je olivov\u00fd olej, avok\u00e1do alebo hlavn\u00e9 jedlo. U\u017e\u00edvanie na pr\u00e1zdny \u017eal\u00fadok v\u00fdrazne zni\u017euje vstreb\u00e1vanie.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Na\u010dasovanie:<\/strong> AKBA m\u00e1 pol\u010das rozpadu pribli\u017ene 6 hod\u00edn, preto <strong>2-3 d\u00e1vky denne<\/strong> Je to zmysluplnej\u0161ie ako jednorazov\u00e1 d\u00e1vka, aby sa udr\u017eala kon\u0161tantn\u00e1 \u00farove\u0148 \u00fa\u010dinnosti.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kombin\u00e1cia s BCP:<\/strong> AKBA (os STAT3\/NF-\u03baB) a BCP (os CB2\/Th17) rie\u0161ia r\u00f4zne sign\u00e1lne dr\u00e1hy v MOGAD a p\u00f4sobia synergicky. Nie s\u00fa zn\u00e1me \u017eiadne farmakologick\u00e9 interakcie.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u017dal\u00fado\u010dn\u00e1 tolerancia:<\/strong> Boswellia je v\u0161eobecne ve\u013emi dobre zn\u00e1\u0161an\u00e1. Pri vy\u0161\u0161\u00edch d\u00e1vkach sa zriedkavo vyskytuje mierne podr\u00e1\u017edenie \u017eal\u00fadka. Preto ju v\u017edy u\u017e\u00edvajte s jedlom alebo v pr\u00edpade potreby d\u00e1vku do\u010dasne zn\u00ed\u017ete.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Schwarzer_Pfeffer_oral\"><\/span>\u010cierne korenie (peror\u00e1lne)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Hlavn\u00e1 \u00fa\u010dinn\u00e1 l\u00e1tka \u03b2-karyofyl\u00e9n (BCP) v oleji z \u010dierneho korenia (<em>Piper nigrum<\/em>) sp\u00f4sobuje pokles z\u00e1palov\u00fdch cytok\u00ednov IL-6, TNF-\u03b1, IL-17, IFN-\u03b3 a transkrip\u010dn\u00fdch faktorov Th17 (ROR-\u03b3t) a Th1 (T-bet), ako aj v\u00fdrazn\u00e9 zv\u00fd\u0161enie protiz\u00e1palov\u00fdch cytok\u00ednov TGF-\u03b21, IL-10, IL-4 a transkrip\u010dn\u00fdch faktorov Th2 (GATA3) a Treg (Foxp3). Tieto \u00fa\u010dinky s\u00fa striktne spojen\u00e9 s aktiv\u00e1ciou receptora CB2.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Receptory CB2 a remyeliniz\u00e1cia s\u00fa priamo mechanicky prepojen\u00e9: agonizmus CB2 podporuje dozrievanie OPC - agonista CB2 novej gener\u00e1cie (Yhhu4952) v\u00fdznamne zv\u00fd\u0161il expresiu myel\u00ednov\u00e9ho z\u00e1kladn\u00e9ho prote\u00ednu (MBP) a podiel zrel\u00fdch oligodendrocytov v corpus callosum.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">D\u00e1vkovanie \u010dierneho korenia: 20 ... 200 mg\/d - \u010do zodpoved\u00e1 20 tr.\/d - tak\u017ee najlep\u0161ie je u\u017e\u00edva\u0165 7 trp. ka\u017ed\u00fdch 8 hod\u00edn (najlep\u0161ie 5 trp. ka\u017ed\u00fdch 6 hod\u00edn pre vy\u0161\u0161ie plazmatick\u00e9 hladiny) v nosnom oleji v kapsule. Ako lipofiln\u00fd spolu s jedlom\/n\u00e1pojom s vysok\u00fdm obsahom tuku.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Schwarzer_Pfeffer_Inhalation\"><\/span>\u010cierne korenie (inhal\u00e1cia)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">D\u00e1vkovanie: Inhalujte 3 trp. ka\u017ed\u00e9 4 hodiny po\u010das d\u0148a (pol\u010das rozpadu je 2-4 hodiny) na Liqui-Pad vyhrievan\u00e9ho difuz\u00e9ra po dobu 20 min\u00fat a po ka\u017edom hlbokom n\u00e1dychu zadr\u017ete dych na 5-8 sek\u00fand, v noci nechajte difuz\u00e9r v miestnosti spusten\u00fd, bez priamej inhal\u00e1cie.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u010cierne korenie m\u00f4\u017ee ma\u0165 stimula\u010dn\u00fd \u00fa\u010dinok a zhor\u0161ova\u0165 sp\u00e1nok. V takom pr\u00edpade ho nerozpty\u013eujte v noci.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ak d\u00f4jde k podr\u00e1\u017edeniu d\u00fdchac\u00edch ciest (suchos\u0165) alebo sa objav\u00ed boles\u0165 hlavy: Zn\u00ed\u017ete d\u00e1vku alebo pred\u013a\u017ete intervaly.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Copaiba-Ol_oral_%E2%80%93_NUR_doTERRA\"><\/span>Olej z kopaiby (or\u00e1lny) - iba doTERRA<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">52,6 % BCP - zodpoved\u00e1 14,7 mg BCP\/kapku - ke\u010f\u017ee BCP je lipofiln\u00fd, v\u017edy ho u\u017e\u00edvajte s jedlom\/n\u00e1pojom s vysok\u00fdm obsahom tuku!<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pod\u013ea klinick\u00fdch \u0161t\u00fadi\u00ed bezpe\u010dnosti z toho vypl\u00fdva nasleduj\u00face odpor\u00fa\u010dan\u00e9 d\u00e1vkovanie v z\u00e1vislosti od telesnej hmotnosti:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOGAD-spezifische_Dosierungstabelle_doTERRA_Copaiba_525_BCP\"><\/span>Tabu\u013eka d\u00e1vkovania \u0161pecifick\u00e1 pre MOGAD (doTERRA Copaiba 52,5 % BCP)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Telesn\u00e1 hmotnos\u0165<\/th><th><strong>Ochrana pr\u00edrody<\/strong> (0,4 mg\/kg)<\/th><th><strong>Akt\u00edvny \u0165ah<\/strong> (1,0 mg\/kg)<\/th><th><strong>Intenz\u00edvna terapia<\/strong> (1,5 mg\/kg)<\/th><\/tr><\/thead><tbody><tr><td><strong>50 kg<\/strong><\/td><td>20 mg = <strong>1-2 kvapky<\/strong><\/td><td>50 mg = <strong>3-4 kvapky<\/strong><\/td><td>75 mg = <strong>5 kvapiek<\/strong><\/td><\/tr><tr><td><strong>60 kg<\/strong><\/td><td>24 mg = <strong>2 kvapky<\/strong><\/td><td>60 mg = <strong>4 kvapky<\/strong><\/td><td>90 mg = <strong>6 kvapiek<\/strong><\/td><\/tr><tr><td><strong>70 kg<\/strong><\/td><td>28 mg = <strong>2 kvapky<\/strong><\/td><td>70 mg = <strong>5 kvapiek<\/strong><\/td><td>105 mg = <strong>7 kvapiek<\/strong><\/td><\/tr><tr><td><strong>80 kg<\/strong><\/td><td>32 mg = <strong>2 kvapky<\/strong><\/td><td>80 mg = <strong>5-6 kvapiek<\/strong><\/td><td>120 mg = <strong>8 kvapiek<\/strong><\/td><\/tr><tr><td><strong>90 kg<\/strong><\/td><td>36 mg = <strong>2-3 kvapky<\/strong><\/td><td>90 mg = <strong>6 kvapiek<\/strong><\/td><td>135 mg = <strong>9 kvapiek<\/strong><\/td><\/tr><tr><td><strong>100 kg<\/strong><\/td><td>40 mg = <strong>3 kvapky<\/strong><\/td><td>100 mg = <strong>7 kvapiek<\/strong><\/td><td>150 mg = <strong>10 kvapiek<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOGAD-Phasen-adaptierte_Dosierung\"><\/span>F\u00e1zovo prisp\u00f4soben\u00e9 d\u00e1vkovanie MOGAD<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_1_Akuter_Schub_erste_2%E2%80%934_Wochen\"><\/span><strong>F\u00e1za 1: Ak\u00fatne vzplanutie (prv\u00e9 2-4 t\u00fd\u017edne)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Cie\u013e:<\/strong> Agres\u00edvne potla\u010denie Th17, zn\u00ed\u017eenie IL-6<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>D\u00e1vkovanie:<\/strong> 1,0-1,5 mg\/kg denne<\/li>\n\n\n\n<li><strong>Pridelenie:<\/strong> 3\u00d7 denne (optim\u00e1lne pre nepretr\u017eit\u00fa aktiv\u00e1ciu receptorov CB2)<\/li>\n\n\n\n<li><strong>Pr\u00edklad 70 kg:<\/strong> 5-7 kvapiek denne, rozdelen\u00fdch ako 2+2+3 kvapky<\/li>\n\n\n\n<li><strong>Kombin\u00e1cia:<\/strong> S AKBA (200-300 mg\/de\u0148 na inhib\u00edciu STAT3) + vysok\u00e9 d\u00e1vky kortiz\u00f3nu (\u0161tandard)<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_2_Schubremission_Erhaltung_langfristig\"><\/span><strong>F\u00e1za 2: remisia relapsu \/ udr\u017eiavanie (dlhodob\u00e9)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Cie\u013e:<\/strong> Prevencia relapsu, kon\u0161tantn\u00fd protiz\u00e1palov\u00fd t\u00f3n<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>D\u00e1vkovanie:<\/strong> 0,4-0,7 mg\/kg denne<\/li>\n\n\n\n<li><strong>Pridelenie:<\/strong> 2\u00d7 denne<\/li>\n\n\n\n<li><strong>Pr\u00edklad 70 kg:<\/strong> 2-3 kvapky denne, rozdelen\u00e9 ako 1+2 alebo 2+2<\/li>\n\n\n\n<li><strong>Kombin\u00e1cia:<\/strong> S AKBA (150 mg\/de\u0148) volite\u013ene<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_3_Monophasischer_Verlauf_Titer_fallend\"><\/span><strong>F\u00e1za 3: Monof\u00e1zick\u00fd priebeh (klesaj\u00faci titer)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Cie\u013e:<\/strong> Neuroprotekcia, remyeliniz\u00e1cia<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>D\u00e1vkovanie:<\/strong> 0,2-0,4 mg\/kg denne<\/li>\n\n\n\n<li><strong>Pridelenie:<\/strong> 1-2\u00d7 denne<\/li>\n\n\n\n<li><strong>Pr\u00edklad 70 kg:<\/strong> 1-2 kvapky denne<\/li>\n\n\n\n<li><strong>Mo\u017enos\u0165 vyva\u017eovania<\/strong> po 6-12 mesiacoch stabilnej s\u00e9ronegativity<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Quellen\"><\/span>Zdroje<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Toxikol\u00f3gia (700 mg\/kg NOAEL)<\/strong><br><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27358239\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/27358239\/<\/a><\/li>\n\n\n\n<li><strong>Model EAE (2,5-5 mg\/kg \u00fa\u010dinne)<\/strong><br><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10377147\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10377147\/<\/a><\/li>\n\n\n\n<li><strong>\u0160t\u00fadia na \u013eu\u010foch (100 mg bezpe\u010dne)<\/strong><br><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9104399\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9104399\/<\/a><\/li>\n\n\n\n<li><strong>Klinick\u00e1 \u0161t\u00fadia (\u00fa\u010dinnos\u0165 126 mg\/de\u0148)<\/strong><br><a href=\"https:\/\/accurateclinic.com\/accurate-education-terpenes-caryophyllene\/\" target=\"_blank\" rel=\"noopener\">https:\/\/accurateclinic.com\/accurate-education-terpenes-caryophyllene\/<\/a><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Copaiba-Ol_Inhalation\"><\/span>Olej z kopaiby (inhal\u00e1cia)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Okrem \u010dierneho korenia s maxim\u00e1lnym obsahom 38% BCP je kopaibov\u00fd olej s obsahom a\u017e 87% BCP ove\u013ea silnej\u0161\u00ed, a preto je najlep\u0161ou vo\u013ebou na inhal\u00e1ciu.<br>Difuz\u00e9ry zvy\u010dajne pracuj\u00fa so studen\u00fdm ultrazvukov\u00fdm (US) rozpra\u0161ovan\u00edm. BCP sa v\u0161ak vyparuje a\u017e od teploty pribli\u017ene 130 \u00b0C a hor\u00ed pri teplot\u00e1ch nad 180 \u00b0C. Musia sa preto pou\u017e\u00edva\u0165 vyhrievate\u013en\u00e9 dif\u00fazory s regul\u00e1ciou teploty (napr. <a href=\"https:\/\/storz-bickel.com\" target=\"_blank\" rel=\"noreferrer noopener\">Volcano Classic, Volcano Hybrid alebo Mighty+<\/a>) v cenovom segmente pribli\u017ene 270 - 415 EUR a teplota by mala by\u0165 nastaven\u00e1 \u010do najpresnej\u0161ie (kontrola infra\u010derven\u00fdm teplomerom) na 160 \u00b0C.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Odpor\u00fa\u010dan\u00e9 d\u00e1vkovanie oleja Copaiba (doTERRA) s obsahom 69 % BCP - 1 kvapka obsahuje 18,6 mg BCP.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">BCP m\u00e1 pol\u010das rozpadu 2-4 hodiny. Aby sa dosiahla \u010do najkon\u0161tantnej\u0161ia hladina \u00fa\u010dinnej l\u00e1tky, inhal\u00e1cia by sa mala vykon\u00e1va\u0165 tak, ako je uveden\u00e9 vy\u0161\u0161ie, so 4 kvapkami (\u010do zodpoved\u00e1 pribli\u017ene 200 mg BCP) ka\u017ed\u00e9 4 hodiny. Difuz\u00e9r sa m\u00f4\u017ee po\u010das noci necha\u0165 spusten\u00fd v bl\u00edzkosti postele.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Zieldosen_und_benotigte_Tropfenzahl\"><\/span>Cie\u013eov\u00e9 d\u00e1vky a po\u017eadovan\u00fd po\u010det kvapiek<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Cie\u013eov\u00e1 d\u00e1vka BCP<\/th><th>Kvapky oleja Copaiba<\/th><th>Celkov\u00fd olej (mg)<\/th><\/tr><\/thead><tbody><tr><td>20 mg BCP (po\u010diato\u010dn\u00e1 d\u00e1vka)<\/td><td><strong>~1 kvapka<\/strong><\/td><td>~29 mg<\/td><\/tr><tr><td>50 mg BCP<\/td><td><strong>~3 kvapky<\/strong><\/td><td>~72 mg<\/td><\/tr><tr><td>100 mg BCP (terapeutick\u00fd)<\/td><td><strong>~5-6 kvapiek<\/strong><\/td><td>~145 mg<\/td><\/tr><tr><td>120 mg BCP (horn\u00e1 denn\u00e1 d\u00e1vka)<\/td><td><strong>~6-7 kvapiek<\/strong><\/td><td>~174 mg<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Cie\u013eov\u00e1 inhal\u00e1cia BCP<\/th><th>Mno\u017estvo oleja na tekutej podlo\u017eke<\/th><th>Kvapky<\/th><\/tr><\/thead><tbody><tr><td>~20 mg BCP inhalovan\u00fdch<\/td><td>~40 mg oleja (~78 mg\/0,69)<\/td><td><strong>2-3 kvapky<\/strong><\/td><\/tr><tr><td>~50 mg BCP inhalovan\u00fdch<\/td><td>~100 mg oleja<\/td><td><strong>4-5 kvapiek<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Synergistische_MOGAD-Strategie_Multi-Target\"><\/span>Synergick\u00e1 strat\u00e9gia MOGAD (viac\u00fa\u010delov\u00e1)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ke\u010f\u017ee MOGAD m\u00e1 tri patomechanizmy, v\u00fdsledkom je t\u00e1to kombin\u00e1cia zalo\u017een\u00e1 na d\u00f4kazoch:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>\u00da\u010dinn\u00e1 l\u00e1tka<\/th><th>D\u00e1vka<\/th><th>Cesta sign\u00e1lu<\/th><th>V\u00fdznam MOGAD<\/th><\/tr><\/thead><tbody><tr><td><strong>BCP (peror\u00e1lne)<\/strong><\/td><td>0,4-1,5 mg\/kg<\/td><td>CB2 \u2192 Th17\u2193, IL-6\u2193, Nrf2\/HO-1\u2191<\/td><td>\u2605\u2605\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>AKBA (\u00fastne)<\/strong><\/td><td>200-400 mg\/de\u0148<\/td><td>STAT3\u2193, NF-\u03baB\u2193, 5-LOX\u2193<\/td><td>\u2605\u2605\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>BCP (inhal\u00e1cia, 160 \u00b0C)<\/strong><\/td><td>2-3 kvapky, 2\u00d7 denne<\/td><td>Limbick\u00fd, r\u00fdchly prienik do CNS<\/td><td>\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>Kadidlov\u00fd olej (inhal\u00e1cia)<\/strong><\/td><td>3-4 kvapky, 2\u00d7 denne<\/td><td>Incenzolacet\u00e1t \u2192 TRPV3, PPAR-\u03b3<\/td><td>\u2605\u2605\u2605<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">T\u00e1to \u0161tvorpilierov\u00e1 strat\u00e9gia sa zaober\u00e1:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Th17\/IL-6<\/strong> (BCP peror\u00e1lne + AKBA)<\/li>\n\n\n\n<li><strong>STAT3<\/strong> (AKBA)<\/li>\n\n\n\n<li><strong>Ochrana oligodendrocytov<\/strong> (aktiv\u00e1cia BCP Nrf2)<\/li>\n\n\n\n<li><strong>Limbick\u00e1 modul\u00e1cia<\/strong> (inhal\u00e1cia)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wichtige_MOGAD-spezifische_Hinweise\"><\/span>D\u00f4le\u017eit\u00e9 inform\u00e1cie \u0161pecifick\u00e9 pre MOGAD<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>\u017diadna monoterapia<\/strong> - BCP\/AKBA s\u00fa <strong>Doplnky ku konven\u010dnej terapii<\/strong><br>(kortiz\u00f3n ak\u00fatne, v pr\u00edpade potreby rituximab\/MMF\/IVIG profylakticky) - nikdy ako n\u00e1hrada<\/li>\n\n\n\n<li><strong>Monitorovanie biomarkerov:<\/strong>\n<ul class=\"wp-block-list\">\n<li>MOG-IgG titer ka\u017ed\u00fdch 3-6 mesiacov<\/li>\n\n\n\n<li>sNfL (Neurofilament Light) ako marker aktivity<\/li>\n\n\n\n<li>Zv\u00e1\u017ete zn\u00ed\u017eenie d\u00e1vky, ak titre trvalo klesaj\u00fa<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Pozorujte sp\u00fa\u0161\u0165a\u010d \u0165ahu<\/strong> - Infekcie s\u00fa hlavn\u00fdm sp\u00fa\u0161\u0165a\u010dom<br>V pr\u00edpade infekcie v pr\u00edpade potreby podajte d\u00e1vku <strong>do\u010dasne zv\u00fd\u0161i\u0165 na 1,5 mg\/kg<\/strong> (prevent\u00edvne)<\/li>\n\n\n\n<li><strong>Hodnoty pe\u010dene pre Copaiba<\/strong> - Ak &gt;1 mg\/kg po\u010das &gt;3 mesiacov<br>Kontrola ALT\/AST ka\u017ed\u00e9 3 mesiace<\/li>\n\n\n\n<li><strong>Alternat\u00edva \u010dierneho korenia<\/strong> - V pr\u00edpade ob\u00e1v t\u00fdkaj\u00facich sa kopaiby: olej z \u010dierneho korenia (25-38 % BCP)<br>Potom vypo\u010d\u00edtajte po\u010det kvapiek \u00d7 2<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%CE%B1-Asaron_Kalmus-Ol_Acorus_calamus_%E2%80%93_direkt_oligodendrozytenprotektiv\"><\/span>\u03b1-Asaron (kalam\u00e1rov\u00fd olej, <em>Acorus calamus<\/em>) - priamo oligodendrocytovo protekt\u00edvne<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Jedna z m\u00e1la \u00fa\u010dinn\u00fdch l\u00e1tok s <strong>priamy remyeliniza\u010dn\u00fd \u00fa\u010dinok<\/strong> je . <em><strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37146420\/\" target=\"_blank\" rel=\"noreferrer noopener\">\u03b1-Asaron<\/a><\/strong><\/em>. Zlep\u0161uje dysmyeliniz\u00e1ciu sp\u00f4soben\u00fa stratou zrel\u00fdch oligodendrocytov po hypoxickej isch\u00e9mii prostredn\u00edctvom upregul\u00e1cie a aktiv\u00e1cie PPAR-\u03b3 v astrocytoch. To zvy\u0161uje expresiu glutam\u00e1tov\u00e9ho transport\u00e9ra GLT-1 a odstra\u0148uje nadmern\u00fd glutam\u00e1t z extracelul\u00e1rneho priestoru, ktor\u00fd by inak sp\u00f4sobil glutam\u00e1tom sprostredkovan\u00fa excitotoxicitu v OPC, inhiboval ich diferenci\u00e1ciu a vyvolal bunkov\u00fa smr\u0165. <a href=\"https:\/\/www.klinikum.uni-heidelberg.de\/neurologische-klinik\/neurologie-und-poliklinik\/forschung\/neuroimmunology\/ag-molekulare-neuroimmunologie\/mog-enzephalomyelitis\" target=\"_blank\" rel=\"noreferrer noopener\">Univerzitn\u00e1 nemocnica v Heidelbergu<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">PPARy v neurol\u00f3gii - <a href=\"https:\/\/www.frontiersin.org\/journals\/neuroscience\/articles\/10.3389\/fnins.2022.1060515\/pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Hranice Redakcia 2022<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Pozor:<\/strong> V z\u00e1vislosti od p\u00f4vodu obsahuje kalam\u00e1rov\u00fd olej r\u00f4zne mno\u017estv\u00e1 \u03b2-asaronu, ktor\u00fd je klasifikovan\u00fd ako mutag\u00e9nny. Iba <strong>Vlastnosti bez \u03b2-az\u00f3nu<\/strong> (Acorus calamus var. americanus).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Pod\u013ea s\u00fa\u010dasn\u00e9ho stavu (02.2026) nie je uveden\u00e1 dostupnos\u0165 na trhu.<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Geraniumol_Pelargonium_graveolens_%E2%80%93_Neuroinflammation_und_NO\"><\/span>Ger\u00e1niov\u00fd olej (<em>Pelargonium graveolens<\/em>) - Neuroz\u00e1pal a NO<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7922935\/\" rel=\"nofollow noopener\" target=\"_blank\">Ger\u00e1niov\u00fd olej<\/a> m\u00f4\u017eu by\u0165 u\u017eito\u010dn\u00e9 pri neurodegenerat\u00edvnych ochoreniach, pri ktor\u00fdch je s\u00fa\u010das\u0165ou patofyziol\u00f3gie neuroz\u00e1pal.<br>Hlavn\u00e1 \u00fa\u010dinn\u00e1 l\u00e1tka <em>Citronelol<\/em> vykazovali pri vy\u0161\u0161\u00edch koncentr\u00e1ci\u00e1ch vynikaj\u00facu inhibi\u010dn\u00fa aktivitu na produkciu NO, pri\u010dom rozhoduj\u00face s\u00fa synergick\u00e9 interakcie medzi zlo\u017ekami.<br>Citronelol tie\u017e inhibuje NF-\u03baB - priamo s\u00favis\u00ed s aktiv\u00e1ciou mikrogli\u00ed v MOGAD.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Teebaum-Ol_Melaleuca_alternifolia_%E2%80%93_Mikroglia-Modulation\"><\/span>\u010cajovn\u00edkov\u00fd olej (<em>Melaleuca alternifolia<\/em>) - Modul\u00e1cia mikroglie<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10350368\/\" target=\"_blank\" rel=\"noreferrer noopener\">\u010cajovn\u00edkov\u00fd olej<\/a> a jeho hlavn\u00e9 zlo\u017eky inhibuj\u00fa AChE a BChE, ako aj LOX. Optimaliz\u00e1cia oxida\u010dn\u00e9ho stresu prostredn\u00edctvom antioxida\u010dn\u00fdch vlastnost\u00ed, inhib\u00edcie neuroz\u00e1palov a inhib\u00edcie AChE\/BChE m\u00f4\u017ee ako celkov\u00e1 strat\u00e9gia \u00fa\u010dinne prispie\u0165 k prevencii smrti neur\u00f3nov\u00fdch buniek.<br>Terpinen-4-ol (hlavn\u00e1 \u00fa\u010dinn\u00e1 l\u00e1tka) tie\u017e \u0161pecificky inhibuje polariz\u00e1ciu mikroglie M1.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wirkstoffubersicht_nach_MOGAD-Signalwegen\"><\/span>Preh\u013ead \u00fa\u010dinn\u00fdch l\u00e1tok pod\u013ea sign\u00e1lnych dr\u00e1h MOGAD<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>\u00da\u010dinn\u00e1 l\u00e1tka<\/th><th>Zdroj oleja<\/th><th>Signaliza\u010dn\u00e1 dr\u00e1ha MOGAD<\/th><th>Sila d\u00f4kazov<\/th><\/tr><\/thead><tbody><tr><td><strong>\u03b2-karyofyl\u00e9n (BCP)<\/strong><\/td><td>\u010cierne korenie, Copaiba<\/td><td>CB2 \u2192 Nrf2\/HO-1, PPAR-\u03b3; Th17\u2193, IL-6\u2193<\/td><td>\u2605\u2605\u2605\u2605 (model EAE)<\/td><\/tr><tr><td><strong>AKBA<\/strong><\/td><td>Kadidlo (<em>Boswellia serrata<\/em>)<\/td><td>STAT3\u2193, NF-\u03baB\u2193, 5-LOX\u2193, SPM\u2191, Nrf2\/HO-1\u2191<\/td><td>\u2605\u2605\u2605\u2605 (\u0161t\u00fadie CNS)<\/td><\/tr><tr><td><strong>Acet\u00e1t incenzolu<\/strong><\/td><td>Kadidlo (prchav\u00e1 \u010das\u0165)<\/td><td>TRPV3, PPAR-\u03b3, IL-6\u2193, GFAP\u2193<\/td><td>\u2605\u2605\u2605\u2605 (zvierac\u00ed model)<\/td><\/tr><tr><td><strong>\u03b1-Asaron<\/strong><\/td><td>Calamus (<em>Acorus calamus<\/em>)<\/td><td>PPAR-\u03b3 \u2192 GLT-1\u2191 \u2192 ochrana OPC, priama remyeliniz\u00e1cia<\/td><td>\u2605\u2605\u2605\u2605 (model hypoxie)<\/td><\/tr><tr><td><strong>Linalool<\/strong><\/td><td>Levandu\u013ea, medovka<\/td><td>NMDA modul\u00e1cia, SERT, neuroprotekcia<\/td><td>\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>1,8-cineol<\/strong><\/td><td>Eukalyptus, rozmar\u00edn<\/td><td>Inhib\u00edcia AChE, antioxidant<\/td><td>\u2605\u2605\u2605 (preuk\u00e1zan\u00e9 v mozgu)<\/td><\/tr><tr><td><strong>Citronelol<\/strong><\/td><td>Geranium<\/td><td>NO\u2193, NF-\u03baB\u2193, synergick\u00e9 \u00fa\u010dinky<\/td><td>\u2605\u2605<\/td><\/tr><tr><td><strong>Terpinen-4-ol<\/strong><\/td><td>\u010cajovn\u00edk<\/td><td>Mikroglia M1\u2193, LOX\u2193, AChE\u2193<\/td><td>\u2605\u2605<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Quellen_und_weiterfuhrende_Literatur\"><\/span><strong>Zdroje a \u010fal\u0161ia literat\u00fara<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Banwell B et al - Lancet Neurol. 2023;22:268-282<\/strong> Diagnostick\u00e9 krit\u00e9ri\u00e1 MOGAD<br><strong>PubMed (zdarma):<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36706773\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/36706773\/<\/a> <br><strong>ScienceDirect (abstrakt zdarma, pln\u00fd text s n\u00e1kladmi):<\/strong> <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1474442222004318\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1474442222004318<\/a> <br><strong>DOI:<\/strong> <a href=\"https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8<\/a><\/li>\n\n\n\n<li><strong>Mader S et al - PNAS 2023<\/strong> <em>(Pozn\u00e1mka: v na\u0161om dokumente sa uv\u00e1dza ako \u201ePNAS 2024\" - spr\u00e1vny rok vydania je marec 2023)<\/em> Patomechanizmus komplementu vs. FcR, LMU Mn\u00edchov<br><strong>Pln\u00fd text PNAS (zdarma):<\/strong> <a href=\"https:\/\/www.pnas.org\/doi\/10.1073\/pnas.2300648120\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.pnas.org\/doi\/10.1073\/pnas.2300648120<\/a> <br><strong>Tla\u010dov\u00e1 spr\u00e1va LMU (s vysvetlen\u00edm):<\/strong> <a href=\"https:\/\/www.med.lmu.de\/bmc\/en\/news\/latest-news\/news-overview\/news\/autoimmune-disease-mogad-insights-into-pathomechanisms.html\" target=\"_blank\" rel=\"noopener\">https:\/\/www.med.lmu.de\/bmc\/en\/news\/latest-news\/news-overview\/news\/autoimmune-disease-mogad-insights-into-pathomechanisms.html<\/a> <br><strong>EAN-Kommentar:<\/strong> <a href=\"https:\/\/www.ean.org\/research\/resources\/neurology-updates\/detail\/complement-dependent-and-independent-pathomechanisms-of-myelin-oligodendrocyte-glycoprotein-mog-abs-implications-for-therapeutic-strategies-in-mog-antibody-associated-disease-mogad\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.ean.org\/research\/resources\/neurology-updates\/detail\/complement-dependent-and-independent-pathomechanisms-of-myelin-oligodendrocyte-glycoprotein-mog-abs-implications-for-therapeutic-strategies-in-mog-antibody-associated-disease-mogad<\/a> <\/li>\n\n\n\n<li><strong>Kaneko K et al - Neurol Neuroimmunol Neuroinflamm. 2024;11(5):e200293<\/strong> Aktiv\u00e1cia komplementu CSF<br>\u010cl\u00e1nok e200293 je <strong>nemo\u017eno n\u00e1js\u0165 priamo<\/strong> - K dispoz\u00edcii je v\u0161ak s\u00favisiaci preh\u013eadov\u00fd \u010dl\u00e1nok MOGAD z toho ist\u00e9ho \u010d\u00edsla (e200275 od autorov Moseley\/Zamvil):<br><strong>Neurology NXI (e200275, to ist\u00e9 vydanie):<\/strong> <a href=\"https:\/\/www.neurology.org\/doi\/10.1212\/NXI.0000000000200275\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.neurology.org\/doi\/10.1212\/NXI.0000000000200275<\/a> <br><strong>PubMed search for Kaneko 2024 MOGAD CSF:<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38996203\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/38996203\/<\/a> <em>(vedie na e200275 - odpor\u00fa\u010da sa priame vyh\u013ead\u00e1vanie v PubMed-e200293)<\/em><\/li>\n\n\n\n<li><strong>Cho EB et al - Front Immunol. 2024;15:1320094<\/strong> Doplnkov\u00fd vzor MOGAD vs. NMOSD<br><strong>Frontiers (pln\u00fd text zdarma):<\/strong> <a href=\"https:\/\/doi.org\/10.3389\/fimmu.2024.1320094\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.3389\/fimmu.2024.1320094<\/a> <em>(DOI priamo pr\u00edstupn\u00e9)<\/em><\/li>\n\n\n\n<li><strong>Frontiers Immunol. 2025 - Modely EAE, patogen\u00e9za MOGAD<\/strong> <em>(V\u0161eobecne uveden\u00e9 v dokumente - odkazuje na preh\u013eadov\u00fd \u010dl\u00e1nok o sign\u00e1lnych dr\u00e1hach\/patomechanizmoch)<\/em><br><strong>Frontiers Immunol. 2025 (Sun et al., PMID 40406135):<\/strong> <a href=\"https:\/\/doi.org\/10.3389\/fimmu.2025.1535571\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.3389\/fimmu.2025.1535571<\/a><\/li>\n\n\n\n<li><strong>PMC 2023 - Komplexn\u00fd preh\u013ead Patofyziol\u00f3gia MOGAD<\/strong><br><strong>PMC Pln\u00fd text (zdarma):<\/strong> <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9597055\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9597055\/<\/a><\/li>\n\n\n\n<li><strong>PMC 2024 - aktualizovan\u00fd preh\u013ead Klinick\u00e9 spektrum, patogen\u00e9za, lie\u010dba<\/strong><br><strong>PubMed\/PMC (Trewin et al., Autoimmun Rev 2025):<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39577549\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/39577549\/<\/a><br><strong>Pln\u00fd text PMC:<\/strong> <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9294102\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9294102\/<\/a> <em>(Terapia monoklon\u00e1lnymi protil\u00e1tkami NMOSD\/MOGAD)<\/em><\/li>\n\n\n\n<li><strong>St\u00f6gbauer J et al - Autoimmunity Reviews 2025;103970<\/strong> Terapeutick\u00e9 pr\u00edstupy Dospel\u00ed MOGAD<br><strong>ScienceDirect (otvoren\u00fd pr\u00edstup, pln\u00fd text zdarma):<\/strong> <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1568997225002319\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1568997225002319<\/a> <br><strong>DOI:<\/strong> <a href=\"https:\/\/doi.org\/10.1016\/j.autrev.2025.103970\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.1016\/j.autrev.2025.103970<\/a> <br><strong>Nemeck\u00e9 zhrnutie:<\/strong> <a href=\"https:\/\/www.reine-nervensache.de\/therapieansaetze-bei-mogad-von-der-akutbehandlung-zur-langfristigen-strategie\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.reine-nervensache.de\/therapieansaetze-bei-mogad-von-der-akutbehandlung-zur-langfristigen-strategie\/<\/a> <\/li>\n\n\n\n<li><strong>Odborn\u00e9 stanovisko k nov\u00fdm liekom 2025 - klinick\u00e9 sk\u00fa\u0161anie<\/strong><br><strong>Tandfonline (abstrakt zdarma, pln\u00fd text za poplatok):<\/strong> <a href=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2025.2565189\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2025.2565189<\/a><br><strong>DOI:<\/strong> <a href=\"https:\/\/doi.org\/10.1080\/14728214.2025.2565189\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.1080\/14728214.2025.2565189<\/a><br><\/li>\n\n\n\n<li><strong>\u0160tudijn\u00e1 skupina NEMOS<\/strong> <a href=\"https:\/\/www.nemos-net.de\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.nemos-net.de<\/a><br><\/li>\n\n\n\n<li><strong>Preh\u013ead \u0161t\u00fadie orientovanej na pacienta (cosMOG\/METEOROID):<\/strong><br>Projekt MOG - <a href=\"https:\/\/mogproject.org\/clinical-trials\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/mogproject.org\/clinical-trials\/<\/a><br>ClinicalTrials.gov - cosMOG - <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05063162\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/clinicaltrials.gov\/study\/NCT05063162<\/a><\/li>\n<\/ul>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">V\u0161etok obsah bol svedomito presk\u00faman\u00fd a odr\u00e1\u017ea aktu\u00e1lny (02.2026) stav publikovan\u00fdch poznatkov. Sl\u00fa\u017ei len na informa\u010dn\u00e9 \u00fa\u010dely a nenahr\u00e1dza odborn\u00fa lek\u00e1rsku konzult\u00e1ciu.<br>V\u0161etky odpor\u00fa\u010dania na d\u00e1vkovanie musia by\u0165 ods\u00fahlasen\u00e9 o\u0161etruj\u00facim lek\u00e1rom. <br>S\u00favisiace \u0161t\u00fadie poskytuj\u00fa lek\u00e1rovi \u010fal\u0161ie lek\u00e1rske a vedeck\u00e9 inform\u00e1cie.<\/p>\n<\/blockquote>","protected":false},"excerpt":{"rendered":"<p><span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">\u010cas \u010d\u00edtania<\/span> <span class=\"rt-time\"> 17<\/span> <span class=\"rt-label rt-postfix\">z\u00e1pisnice<\/span><\/span>Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Was ist MOGAD? Jeder kennt elektrische Leitungen: Sie sind mit einer Isolierung versehen, die die einzelne Leiter im Kableb\u00fcndel von einander trennt, damit die Signale in ihnen einander nicht st\u00f6ren und unverf\u00e4lscht von A nach B gelangen.Das R\u00fcckenmark beinhaltet einen ganzen Strang vieler solcher Kabelb\u00fcndel. Sie leiten die Nervensignale vom&hellip;&nbsp;<a href=\"https:\/\/csiag.eu\/sk\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/\" rel=\"bookmark\">\u010c\u00edta\u0165 viac \"<span class=\"screen-reader-text\">MOGAD - choroba spojen\u00e1 s protil\u00e1tkami proti MOG<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[1078,354],"tags":[94,5721,5717,5720,5714,5713,5711,5715,5719,5716,77,90,5712,5718],"class_list":["post-12718","post","type-post","status-publish","format-standard","hentry","category-medizin","category-medizin-gesundheit","tag-antikoerper","tag-bcp","tag-glykoprotein","tag-igg","tag-mog","tag-mogad","tag-molekulare-signalwege","tag-myelin","tag-myelinscheide","tag-oligodendrozyten","tag-pathophysiologie","tag-rezeptoren","tag-therapiekonzepte","tag-transmebranprotein"],"modified_by":"Achim Goerner","_links":{"self":[{"href":"https:\/\/csiag.eu\/sk\/wp-json\/wp\/v2\/posts\/12718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/csiag.eu\/sk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csiag.eu\/sk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csiag.eu\/sk\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/csiag.eu\/sk\/wp-json\/wp\/v2\/comments?post=12718"}],"version-history":[{"count":0,"href":"https:\/\/csiag.eu\/sk\/wp-json\/wp\/v2\/posts\/12718\/revisions"}],"wp:attachment":[{"href":"https:\/\/csiag.eu\/sk\/wp-json\/wp\/v2\/media?parent=12718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csiag.eu\/sk\/wp-json\/wp\/v2\/categories?post=12718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csiag.eu\/sk\/wp-json\/wp\/v2\/tags?post=12718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}